

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

TUTOGEN MEDICAL INC
Form 10-K/A
July 06, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-K/A
(AMENDMENT NO. 1)

Annual report under Section 13 or 15(d) of the Securities Exchange
Act of 1934

For the fiscal year ended September 30, 2005.

Transition report under Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the transition period from _____ to _____

COMMISSION FILE NUMBER: 0-16128

TUTOGEN MEDICAL, INC.
(Name of Registrant as specified in Its Charter)

FLORIDA
(State of Incorporation)

59-3100165
(IRS Employer Identification Number)

13709 PROGRESS BOULEVARD, BOX 19, ALACHUA FLORIDA 32615
(Address of principal executive offices)

(386) 462-0402
(Registrant's telephone number, including area code)

Securities registered under Section 12(b) of
the Exchange Act: COMMON STOCK, \$0.01 par value

Securities registered
under Section 12(g) of the Exchange Act:
NONE

Indicate by check mark whether the registrant: (1) filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes No X
--- ---

Indicate by check mark if no disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. Yes No X
--- ---

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act). Yes No X
--- ---

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

The aggregate market value of the voting and non-voting common equity held by non-affiliates (approximately 8,649,000 shares), computed by reference to the bid and ask of such common equity on the American Stock Exchange, was \$28,282,000 as of November 30, 2005.

As of November 30, 2005, there were 15,950,460 shares outstanding of the issuer's Common Stock, par value \$.01 per share.

DOCUMENTS INCORPORATED BY REFERENCE

None.

EXPLANATORY NOTE

Tutogen Medical, Inc. ("the Company") is filing this Amendment to its Annual report on Form 10-K for the Company's fiscal year ended September 30, 2005, which was originally filed with the Securities and Exchange Commission (the "SEC") on December 22, 2005 (the "Original Filing"), to reflect the restatement of the Company's audited consolidated financial statements for the fiscal year ended September 30, 2005, 2004, and 2003 as well as the notes related thereto, as described in Note 16 ("Restatement") to the accompanying audited consolidated financial statements in Part II, Item 8 of this Form 10-K/A. In addition, Schedule II, "Valuation and Qualifying Accounts for the years ended September 30, 2005, 2004, and 2003" has been included in this Form 10-K/A.

As part of the financial review for the three and six months ended March 31, 2006, the Company became aware of misstatements in previously reported inventory and cost of revenue. The Company discovered that the misstatements were attributable to errors in the calculation of intercompany profit to be eliminated during the consolidation process in prior periods. While investigating the inventory errors, the Company also discovered other errors affecting the Company's deferred tax benefit, accrued expenses, general and administrative and distribution and marketing expenses for the fiscal year ended September 30, 2005. As a result, the Company has restated the accompanying consolidated financial statements for the years ended September 30, 2005, 2004, and 2003 to correct these errors in this Form 10-K/A.

In addition, the Company's management has determined that the accounting errors referenced above were the result of a material weakness in the company's internal control over financial reporting related to its inventory valuation and certain journal entries recorded in the financial close process. The Company has taken steps to remediate the weakness as of the date of this report. See Item 9A "Controls and Procedures".

This Form 10-K/A sets forth the Original Filing in its entirety. However, this Form 10-K/A amends and restates certain information in Items 6, 7, 8, and 9A of Part II and 15A and 15B of Part III of the Original filing, in each case, solely as a result of, and to reflect, the restatement and amends Item 15B of Part III to add Schedule II "Valuation and Qualifying Accounts for the Years Ended September 30, 2005, 2004 and 2003." No Other information in the Original Filing is amended hereby.

Except for the amended information referred to above, this Form 10-K/A continues to describe conditions as of the date of the Original Filing and the company has not modified or updated other disclosures presented in the Original Filing. This Form 10-K/A does not reflect events occurring after the date of the Original Filing or modify or update disclosures (including, except as otherwise provided herein, the exhibits to the Original Filing) affected by subsequent events. Accordingly, this Form 10-K/A includes updated certifications from the Company's Chief Executive Officer and Chief Financial Officer at Exhibits 31.1, 31.2, and

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

32.

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

The discussion contained in this annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for the issuer's fiscal year ended September 30, 2005 (this "Report"), contains forward-looking statements that involve risks and uncertainties. The issuer's actual results could differ significantly from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in "Description of Business" and "Management's Discussion and Analysis or Plan of Operation" as well as those discussed elsewhere in this Report. Statements contained in this Report that are not historical facts are forward-looking statements that are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. A number of important factors could cause the issuer's actual results for 2006 and beyond to differ materially from those expressed in any forward-looking statement made by or on behalf of the issuer.

PART I

ITEM 1. BUSINESS.

Tutogen Medical, Inc., a Florida corporation, was formed in 1985, and with its consolidated subsidiaries (collectively, the "Company" or "Tutogen"), develops, manufactures and markets sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its Tutoplast(R) Process of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology, head and neck and general surgery procedures.

One of the Company's wholly owned subsidiaries, Tutogen Medical GmbH, designs, develops, processes, manufactures, markets, and distributes specialty surgical products and services to over 30 countries through a worldwide distribution network. Another subsidiary, Tutogen Medical (United States), Inc., was formed in 1994 to process, market and distribute allografts for the U.S. market.

The Company's corporate headquarters is currently located in West Paterson, New Jersey. However, the Company announced that effective December 31, 2005, the worldwide headquarters will be in Alachua, Florida. In addition, the Company has a manufacturing facility in Alachua, Florida, international executive offices and processing and manufacturing facilities in Neunkirchen, Germany, and a sales office in Boulogne, France.

The Company contracts with independent tissue banks and procurement organizations to provide donated human tissue for processing under the Company's proprietary TUTOPLAST process. The TUTOPLAST process utilizes solvent dehydration and chemical inactivation which is applied to two types of preserved allografts: soft tissue; consisting of fascia lata, fascia temporalis, pericardium, dermis, sclera, ligaments, tendons and cartilage, and bone tissue; consisting of various configurations of cancellous and cortical bone material. Processed pericardium, fascia lata and dermis are collagenous tissue used to repair, replace or line native connective tissue primarily in neurosurgery, ophthalmology, urology procedures, plastic and reconstructive surgeries, dermis is also used in pelvic floor reconstruction, sclera is used in ophthalmology procedures such as, anterior and posterior segment patch grafting applications for glaucoma, retina and trauma surgery and oculoplastics as well as contour wrapping of an orbital implant, while ligaments, tendons and cartilage are used primarily in orthopedic and trauma repairs. Processed cortical and cancellous bone material is used in a wide variety of applications in spinal and dental

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

surgeries. All processed tissues have a shelf life of five (5) years and require minimal time for rehydration. The Company processes bone and soft tissues in both manufacturing facilities.

The TUTOPLAST(R) processed allografts have been used successfully in over 1,000,000 procedures performed for over thirty (30) years.

In contrast to other processors using freeze-drying, deep freezing or cryopreservation for human tissues, the TUTOPLAST process utilizes a technique in which tissues are soaked and washed in a series of aqueous solutions and organic solvents, removing water and substances that could cause rejection or allergic reaction. This technique dehydrates the tissue keeping the tissue's structure intact, allowing it to act after implantation as a scaffold, which is replaced by newly formed autologous tissue. During processing, the tissues are treated with agents shown to inactivate viruses such as hepatitis and HIV, the virus that causes AIDS, to render the allografts safe for the recipient. Soft tissue is also treated with chemicals shown to be effective against the agent causing Creutzfeldt-Jakob Disease ("CJD"). Once packaged, tissues are terminally sterilized by low dosage radiation, which allows them to be labeled "sterile".

MANUFACTURING AND PROCESSING

Tutogen Medical is a leader in the manufacture and marketing of human allograft and animal xenograft tissue implant products, which significantly improve surgical outcomes for the medical professional and quality of life for patient recipients. Our proprietary TUTOPLAST(R) tissue preservation and sterilization process has the greatest longevity of any similar methodology in the industry today. In use for more than thirty (30) years, there have been well over one million (1,000,000) Tutogen products implanted without a single documented case of disease transmission.

Donated bone and soft tissues are received and quarantined by Tutogen Quality Control (QC) until release by the Quality Assurance (QA) department and Tutogen's Medical Director, a licensed physician. In the interim, tissues are stored in a controlled environment, limited-access area according to requirements set forth by the American Association of Tissue Banks (AATB). Each tissue is given a unique identification number in order to maintain full traceability. Once released for processing, tissues are transferred to manufacturing and kept in a refrigerated or frozen state until issued to a specific production work order.

Following assignment to a manufacturing work order, tissue materials go through appropriate preprocessing operations and into the multi-stage Tutoplast process. This process removes blood, lipids and extraneous materials, inactivates viruses and prions and yields a dehydrated semi-processed product that may be stored at room temperature for extended periods of time. This tissue is subsequently processed to size and/or shape and packaged for terminal sterilization. All Tutogen packaged products are subjected to low dose gamma irradiation, which further enhances tissue safety and eliminates ancillary contamination that may be present from pre-sterilization handling. This terminal sterilization is performed by a third-party contractor, utilizing a validated cycle, which yields a Sterility Assurance Level (SAL) of 10⁻⁶, or one chance in one million of a viable microorganism remaining on the product.

While some of the TUTOPLAST processing steps are automated, the majority are manual, and rely on highly-skilled personnel for their proper execution. Such skilled labor is readily available in the surrounding geographic areas and management feels that there should be no adverse affect on the business related to the labor market.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Tutogen operates two tissue processing facilities; a 26,000 square foot facility in Alachua, Florida and a 32,000 square foot facility in Neunkirchen, Germany. Major expansion projects are currently underway at both facilities, with completion dates of the first and third calendar quarters of 2006, respectively. These expansion projects are intended to insure the availability of sufficient production capacity in order to address the increasing demand for the Company's allograft and xenograft products.

QUALITY ASSURANCE - Tutogen Medical maintains a comprehensive quality assurance program that provides oversight to all pertinent aspects of the Company's day-to-day operational activities. Among the responsibilities of the QA organization are:

- o Maintenance of an extensive documentation and change-control system (specifications, standard operating procedures and engineering drawings)
- o Internal and external auditing for compliance with international and domestic regulatory body or accrediting organization regulations or requirements
- o Review and approval of donor medical record information and screening/test documentation
- o Product and process document review and release for distribution
- o Evaluation and follow-up of all Tutogen-related product complaints
- o Management of a Corrective and Preventive Action program to reduce or eliminate any identified non-conformances

The Quality Assurance department is independent from the manufacturing operation, operating under the supervision of the Tissue Bank Director (a medical doctor).

MARKETING AND DISTRIBUTION

Tutogen's products and processing services are provided globally through a combination of worldwide marketing and distribution partners ("partners"), direct representatives and local distributors. Tutogen's personnel, with distributors and their representatives, conduct product training sessions, make joint customer calls, set objectives and evaluate their representatives' performance. Personnel also call on selected physicians and key hospital accounts in order to provide needed clinical and technical information services. The overall strategy is to work with each global partner to expand penetration into currently covered regions, develop additional global opportunities, and to broaden the product portfolio with procedure-specific products. In markets not covered by its global distributors, Tutogen's focus is on adding local distributors or direct operations capable of market penetration.

Approximately 70% of the Company's revenues are derived within the United States, while the remaining Global sales are derived mostly from Europe. Since Tutogen's foreign donor qualification standards are in full compliance with the donor suitability standards of the Food and Drug Administration ("FDA"), the Company has worked with its partners to expand into numerous market opportunities in the United States. Tissue grafts are used in Urology, Gynecology, Ophthalmology, Orthopaedics, Spine, Dental, General Surgery, and Head and Neck applications. Future objectives are to match this penetration into additional global and specialty markets, using either TUTOPLAST Processed Human Allograft or Xenograft tissue implants.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

The Company's U.S. marketing efforts have concentrated on building a Marketing and Distribution organization, capable of supporting its various partners. The Company has entered into several exclusive marketing and distribution agreements with global medical device companies. These agreements have established exclusive distribution for TUTOPLAST processed implants in specialized indications and surgical specialties, for select global markets.

Zimmer Spine Inc. ("Zimmer Spine"), and Zimmer Dental Inc. ("Zimmer Dental"), subsidiaries of Zimmer Holdings, Inc., provide marketing services for the Company's products for the spine and dental markets. Starting in September 2000, Zimmer Spine began representing Tutogen bone products for applications in the Spine Market. Initially Tutogen shipped and billed the customers directly, but in April 2003 the Company entered into an Exclusive License and Distribution Agreement with Zimmer Spine. Effective with this agreement Zimmer Spine became a "stocking distributor", whereby Zimmer Spine now purchases the Company's products and invoices the customer directly. Zimmer Spine distributes both traditional bone and specialized bone products processed with the Company's TUTOPLAST process. Revenues from Zimmer Spine represent 10% and 14%, respectively, of total consolidated and U.S. revenues.

Also in September 2000, Zimmer Dental entered into an agreement to represent Tutoplast Bone, under the brand name Puros(R), for Dental applications. Revenues from this relationship account for 43% of total Global and 62% of total U.S. revenues for the fiscal year ended September 30, 2005. Zimmer Dental represents the products to the end user and Tutogen ships and bills the customer directly. Distribution fees earned pursuant to the agreements are recognized ratably over the terms of these respective agreements.

For urological and gynecological indications, the Company has partnered, since 1998, with Mentor Corporation ("Mentor"). In fiscal year 2005, Mentor accounted for 8% and 12%, respectively, of the Company's total and U.S. revenues. As a stocking distributor, they currently market TUTOPLAST Fascia Lata, Pericardium, and Dermis tissue implants. In April 2005, Tutogen and Mentor signed an agreement that extended current contracts for one year. The intent of this extension is to provide enough time to develop and sign a new definitive agreement, incorporating points from the original 1998 agreement and the succeeding four (4) amendments.

2

Other agreements signed in the past fiscal year include a new Distribution Agreement with IOP, Inc. (IOP). IOP has been a distributor since 1998, and the new agreement extends for another two (2) years their exclusivity to distribute TUTOPLAST processed tissue for Ophthalmology applications. During 2005, IOP represented approximately 5% of total Company revenue. A new partner, Sense Medical signed an exclusive distribution agreement in December 2004, expanding TUTOPLAST products into selected Head and Neck procedures. First year sales for Sense Medical represented 1% of total Company revenue.

Internationally, the Company has implemented a marketing and sales restructuring plan, concentrating on an in-depth penetration of markets with major needs, not covered by Tutogen's Global partners. In Europe, the specific focus is on countries such as Germany, France, Italy, Spain and the U.K., and in major specialty areas, such as Dental and Orthopaedics. The Company believes that through a combination of international distribution strategies, Tutogen can increase its penetration of the international markets for processed tissue.

TISSUE PROCUREMENT

The Company sources donor tissues from multiple independent recovery

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

organizations in Europe and the United States. Recovery agencies obtain donor consent, verify proper donor identity, conduct extensive medical and social history evaluations and recover appropriate donated tissues. Each donor tissue is assigned a unique identification number in order to assure full traceability, from recovery to end user. These records accompany each donor tissue receipt, along with related serological test samples. The test samples are evaluated by independent CLIA (Clinical Laboratory Improvement Amendment) certified laboratories for such transmissible diseases as Hepatitis B surface Antigen (HBsAg), Hepatitis B total core (HBc, IgG/IgM), Hepatitis C virus antibody (HCV Ab), Hepatitis B Nucleic Acid Test (HBV/HCV NAT), Human Immunodeficiency Virus 1&2 antibodies (HIV 1&2 Ab), HIV Nucleic Acid Test (HIV NAT), Human T-Lymphotropic Virus 1&2 (HTLV 1&2) and Syphilis (RPR/STS).

In June of 2002, the Food and Drug Administration (the "FDA") published its draft Guidance for Industry document, "Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and variant Creutzfeldt-Jakob Disease (vCJD) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)". This document reflects the Agency's current thinking on donor deferral criteria for individuals that may have been exposed to a Bovine Spongiform Encephalopathy (BSE) agent, or "Mad Cow" disease. The document draft is in the review and comment stage, which precedes the adoption of a final version of the FDA's position on this matter. As a part of this document, the FDA provided a listing of countries applicable to donor deferral. None of the tissue products that Tutogen distributes in the United States or Canada incorporate tissues from countries identified by the FDA.

With regard to xenograft tissue, Tutogen Germany currently obtains bovine material from a "closed herd" in an internationally approved source country. The U.S. operation is currently in discussions with a potential U.S. bovine tissue provider. This provider would supply specific bovine tissue from a domestic, FDA registered and USDA inspected "closed herd". Failure to secure an animal tissue source could have a material adverse effect on the Company's U.S. operations.

The worldwide demand for allografts, tissue derived from human sources, is anticipated to represent a significant challenge. Faced with this constraint, the Company embarked on a program in 1993 to develop xenografts, tissue derived from animals, as an allograft substitute. The current revenue mix worldwide is approximately 85% allografts and 15% xenografts. As with allografts, xenografts processed using the Company's proprietary TUTOPLAST process have their biomechanical properties and remodeling capacity preserved with removal of antigenicity and infection risk. Studies have shown, that TUTOPLAST processed xenografts are at least equivalent to Allografts as demonstrated by actual clinical use and laboratory studies. To date, the Company has received CE-Marks, the European equivalent to an FDA medical device approval, for bovine pericardium (1998), bovine cancellous bone (1997) and bovine compact (cortical) bone (1999) which permits distribution throughout Europe of products derived from such tissues. In the US the Company has received FDA 510(k) clearances for bovine pericardium, allowing the Company to market the first xenograft tissues, Tutopatch(R) and Tutomesh(R), for indications of general and plastic surgery. Tutopatch(R) and Tutomesh(R) are intended to be produced from bovine pericardium obtained from U.S. cattle, a source deemed free of Bovine Spongiform Encephalopathy ("BSE") and inspected/cleared by the United States Department of Agriculture (USDA).

The superior biomechanical properties of bovine tissues combined with the absence of those supply constraints associated with allografts, permits the use of xenograft tissues, in areas that cannot be optimally addressed with human tissue.

Tutogen allograft tissue recovery partners are FDA or government registered, state licensed and the American Association of Tissue Banks (the "AATB") accredited, as appropriate. Tissues are NOT purchased from these companies, but

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

rather they are reimbursed for the costs incurred in the tissue recovery process itself at the time of delivery. Due to the growing demand for and limited supply of allograft tissue, the Company is continually seeking to form additional alliances with reputable hospital, tissue bank and organ procurement organization tissue recovery firms. Although the Company believes that it has the necessary contractual arrangements in place to insure that there are sufficient tissues available to meet its needs for the foreseeable future, there can be no assurance that these supplies will materialize as planned. Unavoidable interruptions in tissue supply (natural disasters, regulatory changes, financial set-backs, etc.) could have a material adverse effect on Tutogen's business operations.

BACK ORDERS

While Tutogen worldwide has back orders on certain tissue types and tissue sizes, the allograft demand is most significant in the U.S. market. The U.S. is the largest market in the world for allografts and has historically represented the Company's largest market. The Company currently has back orders that are expected to be filled within the next three months; however, the Company cannot predict with absolute certainty its ability to fill specific orders in this time frame. As of September 30, 2005, the Company's back order for all tissues was under \$100,000. Because orders may be canceled or rescheduled, the Company believes that backlog is not always an accurate indicator of results of operations for specific future periods.

3

COMPETITION

Tutogen is a leader in safe bioimplants for tissue repair. Tutogen's competitive advantage is based on its TUTOPLAST process of tissue preservation and viral inactivation. The Tutoplast process consists of multiple steps that assure a safe, viable product and, at the same time, preserves the tissue structure, biomechanics and remodeling characteristics. The TUTOPLAST process is very robust, and has been proven effective in removing antigenicity and inactivating conventional and unconventional viruses and prions. The implants are terminally sterilized, have a five (5) year shelf life, and can be stored at room temperature. The TUTOPLAST process has an outstanding safety record. Since its introduction over thirty (30) years ago, more than 1,000,000 procedures have been successfully performed using TUTOPLAST processed tissues, with no known complications from disease transmission or tissue rejection attributable to the implants. TUTOPLAST processed implants have been described in more than 400 published scientific papers.

The majority of the medical procedures suitable for allografts are currently being performed with autografts (tissues derived from the patient) requiring a second surgical procedure. The advantages of autografts include the decreased incident of tissue rejection and disease transmission. The disadvantages are the dual surgical procedures, increased pain and recovery time and the limitation on the amount and quality of tissue. Allograft advantages include the elimination of a second surgical site resulting in lower infection rates, the possible reduction in surgical procedure time, faster recovery times and lower costs, while disadvantages include availability and possible rejection. Availability and safety are the primary factors in the ability of TUTOPLAST processed allografts to compete with autografts for use by the surgical community.

The industry in which the Company operates is highly competitive. Processors of allograft tissue for transplantation in the U.S. include commercial processors such as Osteotech, Inc., Regeneration Technologies, Inc. and LifeCell, Inc., companies well established in the fields of processing and distribution of bone

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

and soft tissue implants, and which have substantially greater financial resources than the Company. Not-for-profit tissue banks that procure and process tissue for distribution are considered competitors for certain applications and in certain markets. Management believes that the TUTOPLAST process, with its impressive record for safety in the surgical community, gives the Company a competitive advantage over its competitors. However, due to government regulation, disrupted sources of availability and increasing competition, there can be no assurance that the Company will be able to continue to compete successfully. In addition, there can be no assurance that in the future the Company's allografts will be able to compete successfully with new tissue substitutes being developed by other companies.

GROWTH STRATEGY

The Company estimates the worldwide market for its present products to be approximately \$1 billion, including all procedures in the various fields of use. The Company's existing tissue supply network, established processing facilities and proven TUTOPLAST technology provides the foundation for continued growth into fiscal 2006 and beyond. Future growth will be aided by new sources of tissue, new procedures and products, and expansion into new markets. The Company will focus on applications for both Human allograft and Xenograft tissue implants.

Besides Tutogen's internally developed new products and technology, a major component of Tutogen's growth strategy will be its collaboration with each Global partner. Tutogen will continue to work with each organization to evaluate opportunities for new products and applications. The ultimate goal is to provide each partner with a full line of procedure specific implants, for their respective fields of use.

Currently, Tutogen's focus is on the introduction of new products and applications for TUTOPLAST processed tissues. In January 2005, the Company developed, in association with Zimmer Dental, a new bone block to augment ridge restoration. In the U.S. the Puros block graft has been very well accepted and is highlighted in various Zimmer Dental training courses. Globally, similar products processed from Xenograft tissue, has helped generate growth as Tutogen focuses on expanding the international market for dental products. Additionally, Tutogen has developed membranes from TUTOPLAST processed dermis and pericardium for use as a barrier in dental applications. These products are being used in Europe and a U.S. launch is planned for early in 2006.

In October 2002, the Company entered the European market with Tutomesh(R), a TUTOPLAST processed biological membrane for hernia and abdominal wall repair. It has been very well received in Europe, and has already been successfully used in abdominal wall surgery of neonates and children with hernia defects. In December 2004, Tutogen received FDA 510(k) marketing clearance for a product and is currently investigating various options for distribution in the U.S. It is estimated that, in the U.S. approximately 1,000,000 hernia procedures are performed each year, creating an estimated \$150,000,000 market. Focus for the Company is on globally developing this opportunity for both the Tutomesh, as well as for TUTOPLAST processed Dermis.

The Orthopaedic market for Biologic Materials is currently estimated at just over \$1 billion for 2005. Allograft makes up about 33% of this revenue, split between traditional allograft bone and machined specialty grafts, another 23% of this market is Demineralized Bone Matrix (DBM). Tutogen has development programs in each of these areas. In the Spinal Market, Tutogen continues its collaboration with Zimmer Spine in developing new, highly precise and specialized implants for spinal fusion. In the Orthopaedic arena, Tutogen has internally developed a line of TUTOPLAST processed, machined bone implants for the repair of orthopaedic fractures and soft tissue ruptures. The Tutofix(R) line of implants was released in Europe in 2004. The current strategy is to

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

broaden its release internationally, and to develop a distribution strategy for the U.S. market.

The Company's tissues and products have application in numerous surgical indications. The Company, in association with its partners and distributors, enjoys high degrees of success in various markets, including ophthalmology, urological/gynecological, spine, and dental. The Company will continue its efforts in developing new products for these specialties, and in investigating potential new markets for its TUTOPLAST processed tissue.

4

INTERNATIONAL OPERATIONS

Approximately 32%, 42% and 30% of the Company's net sales, respectively for fiscal years 2005, 2004 and 2003 were derived from outside the United States. The Company currently has sales in more than 30 countries located primarily in the United States and Europe. As a result of its foreign sales and facilities, the Company's operations are subject to the risks of doing business internationally, including foreign currency fluctuation risk.

| (IN THOUSANDS) | United States | International | Consolidated |
|--------------------------|---------------|---------------|--------------|
| Revenues | | | |
| Year ended September 30, | | | |
| 2005 | \$ 21,752 | \$ 10,108 | \$ 31,860 |
| 2004 | \$ 17,126 | \$ 12,204 | \$ 29,330 |
| 2003 | \$ 21,168 | \$ 9,092 | \$ 30,260 |

For a discussion of the Company's long-lived assets as of September 30, 2005, 2004 and 2003 see Note 9 of "Notes to Consolidated Financial Statements" and for the deferred tax assets for the years ended September 30, 2005, 2004 and 2003 see Note 10 of "Notes to Consolidated Financial Statements". For discussion of the Company's sales by product, see the analysis of revenue in Item 7.

RESEARCH AND DEVELOPMENT

Tutogen continues to engage in research and development ("R&D"). The Company's scientific personnel and university level consultants contractively collaborate on research activities related to allograft and non-allograft tissue development. The Company follows an Internal Product Development plan and organizes all R&D activities, including the Zimmer Spine and Zimmer Dental collaboration. R & D expenditures increased 16% from \$1,432,000 in 2004 to \$1,659,000 in 2005.

In allograft-related areas, R&D activities focus primarily on the development of surgical solutions, standardized and tailor-made products instead of offering grafting material to the surgeon. Also, continuing progress on the application of the Company's proprietary TUTOPLAST process to various other tissues has met with success. The Company continues to independently review its processing technology to improve tissue safety and efficacy. Non-allograft activities relate to explorations into the use of xenografts, tissue-engineered grafts and improving healing. Clinical studies, evaluation and follow-up are conducted on these activities. The Company's research efforts are subsidized by its collaboration with non-profit research institutions. These activities will be expanded substantially pending the availability of the necessary financial resources. The Company is referred to in more than 400 publications.

CUSTOMERS

Zimmer Spine and Mentor are principal customers to the Company, accounting for

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

approximately 10% and 8%, respectively, of the Company's net sales for the year ended September 30, 2005. No other customer accounted for more than 10% of the Company's net sales for the fiscal year 2005. In June 2005, the Company entered into an Amendment of its Exclusive License and Distribution Agreement with Zimmer Spine redefining the terms governing its relationship. The Company has Exclusive Distribution Agreements with Mentor granting a license to exclusively distribute the TUTOPLAST Processed Fascia Lata, Pericardium and Dermis in their field of use, which is defined as all urological and gynecological applications and procedures in the United States and certain foreign markets.

PATENTS, LICENSES AND TRADEMARKS

Wherever possible, Tutogen seeks to protect its proprietary information, products, methods and technology by obtaining patent and trademark protection. Tutogen has 18 patents pending and has 15 registered trademarks covering several countries worldwide. In the United States, the Company has two FDA accepted 510(k) applications for its various products or processes. The Company believes that it has established itself through the TUTOPLAST trademark identity and a record of safety and quality assurance that will survive beyond the life of the patents.

GOVERNMENT REGULATION

Tutogen procures, processes and markets its tissue products worldwide. Although some standards harmonization exists, each country in which the Company does business has its own specific regulatory requirements. These requirements are dynamic in nature and, as such, are continually changing. New regulations may be promulgated at any time and with limited notice. While the Company believes that it is in compliance with all existing pertinent international and domestic laws and regulations, there can be no assurance that changes in governmental administrations and regulations will not negatively impact the Company's operations.

In the United States, the Company's allograft products are regulated by the Food and Drug Administration under Title 21 of the Code of Federal Regulations, Parts 1270 and 1271, "Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Products". Xenograft tissues are regulated as medical devices and subject to 21 CFR, Part 820 (Current Good Manufacturing Practices for Medical Devices) and related statutes. The Company has obtained a 510(k) marketing clearance from the FDA for bovine pericardium, for use in general and plastic surgery

5

applications and will be seeking further approvals for other xenograft tissues and indications. In addition, the U.S. operation is subject to certain state and local regulations, as well as compliance to the Tissue Bank industry's accrediting organization, the AATB.

In Germany, allografts are classified as drugs and the German government regulates such products in accordance with German Drug Law. On April 7, 2004, the European Commission issued a human tissue directive to regulate allografts within the EU. Tutogen's Neunkirchen facility is presently licensed by the German Health Authorities and in compliance with applicable international laws and regulations, allowing the Company to market its human and animal implant products globally.

The FDA and international regulatory bodies conduct periodic compliance inspections of both the Tutogen U.S. and German processing facilities. Both operations are registered with the U.S. FDA Center for Biologics Evaluation and

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Research (CBER) and are certified to ISO 9001:2000 and ISO 13485:2003. The Alachua facility is also accredited by the American Association of Tissue Banks and is licensed in the states of Florida, New York and California. The Neunckirchen facility is registered with the German Health Authority (BfArM) as a pharmaceutical and medical device manufacturer and is subject to German drug law. The Company believes that worldwide regulation of allografts and xenografts is likely to intensify as the international regulatory community focuses on the growing demand for these implant products and the attendant safety and efficacy issues of citizen recipients. Changes in governing laws and regulations could have a material adverse effect on the Company's financial condition and results of operations. Company management further believes that it can mitigate this exposure by continuing to work closely with government and industry regulators in understanding the basic tenets of the business and participating in the drafting of reasonable and appropriate legislation.

ENVIRONMENTAL REGULATIONS

The Company's allografts and xenografts as well as the chemicals used in processing are handled and disposed of in accordance with country-specific, federal, state and local regulations. Since 1995, the Company has used outside third parties to perform all biohazard waste disposal.

The Company contracts with a third party to perform all gamma-terminal sterilization of its allografts. In view of the engagement of a third party to perform irradiation services, the requirements for compliance with radiation hazardous waste does not apply, and therefore the Company does not anticipate that having any material adverse effect upon its capital expenditures, results of operations or financial condition. However, the Company is responsible for assuring that the service is being performed in accordance with applicable regulations. Although the Company believes it is in compliance with all applicable environmental regulations, the failure to fully comply with any such regulations could result in the imposition of penalties, fines and/or sanctions which could have a material adverse effect on the Company's business.

TECHNOLOGICAL CHANGE AND COMPETITION

The biomedical field continues to experience rapid and significant technological change. Tutogen's success will depend upon its ability to establish and maintain a competitive position in the marketplace with its products and its ability to develop and apply its technology. There are many well-established companies and academic institutions with greater resources that are capable of developing products based on similar or new technology that could effectively compete with those products offered by the Company.

FOREIGN EXCHANGE RATES AND FOREIGN TRANSACTIONS

A significant portion of the Company's revenues is derived from its German operations, all of which are denominated in Euros. Fluctuations in the U.S. Dollar/Euro exchange rate may therefore have a significant effect on the Company's dollar results. Transactions with foreign suppliers and foreign customers could be materially adversely affected by possible import, export, tariff and other restrictions that may be imposed by the United States or other countries.

EMPLOYEES

As of September 30, 2005, the Company employed a total of 193 full-time and 20 part-time employees, of whom 49 full-time and 7 part-time were employed in the United States and the remainder in Germany. Management believes its relations with its employees are good.

ITEM 1B. UNRESOLVED STAFF COMMENTS.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

As of September 30, 2005, there were no comment letters outstanding from the SEC.

ITEM 2. PROPERTIES.

UNITED STATES. The Company's domestic facilities are located in New Jersey and Florida. In West Paterson, New Jersey, the Company leases approximately 1,400 square feet of office space in which its administrative headquarters is located. The lease will expire in December 2006 and has a base rent of approximately \$2,500 per month. The Company announced the relocation of the administrative offices to its facility in Alachua, Florida which occurred at December 31, 2005. In April 2005, the Company's offices and manufacturing facility in Alachua, Florida expanded from approximately 20,205 square feet to 25,525 square feet of leased space. The Florida lease expires January 31, 2009 with an option through January 31, 2011 at a current base rent of approximately \$36,500 per month. The Company believes it is adequate in space and condition for its current needs.

GERMANY. The Company's facility in Neunkirchen consists of six buildings totaling approximately 32,000 square feet on approximately two acres of land. This property is owned by the Company and should be sufficient in size and condition to handle anticipated production levels for international markets into the foreseeable future. In addition, the Company is renting office space of approximately 23,000 square feet at \$ 12,500 per

6

month expiring at various periods in the later part of 2006. The intent is to eliminate and consolidate the current rental offices as part of expansion efforts underway. The expansion project is expected to be completed by the fourth fiscal quarter 2006.

ITEM 3. LEGAL PROCEEDINGS.

In 2003, the Company received a proposed judgment in Germany as the result of a dispute between the Company and a former international distributor. The estimated settlement, including legal costs was accrued as a litigation contingency. In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the original proposed judgment received against the Company. At September 30, 2005 and 2004, the Company maintains an accrual of \$476,000 with respect to the remaining appeal and legal costs. Management believes that such accrual is sufficient and the final settlement will not have a material impact on its results of operations or financial opinion.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

There was no submission of matters to a vote of security holders during the fourth quarter of the fiscal year covered by this report.

7

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

MARKET INFORMATION

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Since August 17, 2000, the Company's Common Stock has been traded on the American Stock Exchange under the symbol "TTG". The following table sets forth the range of high and low closing price information for the Company's Common Stock for each quarter within the last two fiscal years.

| Fiscal 2004 ----- | High ---- | Low --- |
|----------------------|--------------|------------|
| First Quarter | \$ 5.50 | \$ 4.05 |
| Second Quarter | 5.06 | 3.85 |
| Third Quarter | 4.59 | 3.89 |
| Fourth Quarter | 4.16 | 2.79 |
| | | |
| Fiscal 2005 ----- | High ---- | Low --- |
| First Quarter | \$ 3.13 | \$ 2.24 |
| Second Quarter | 2.60 | 2.30 |
| Third Quarter | 2.42 | 2.11 |
| Fourth Quarter | 4.56 | 2.35 |

Such market quotations reflect inter-dealer prices, without retail mark-ups, markdowns or commissions and may not necessarily represent actual transactions.

HOLDERS

As of November 30, 2005, the approximate number of holders of record of the Company's Common Stock was 828. The Company estimates that there are approximately 2,700 beneficial holders.

DIVIDENDS

The Company has not paid any cash dividends to date and does not anticipate or contemplate paying cash dividends in the foreseeable future until earnings would generate funds in excess of those required to provide for the growth needs of the Company.

EQUITY COMPENSATION PLAN INFORMATION

The following table sets forth certain information regarding the Company's equity compensation plan as of September 30, 2005.

| Plan Category | Number of securities to be Issued upon exercise of Outstanding options, warrants and rights | Weighted-average Exercise price of Outstanding options, Warrants and rights |
|--|--|---|
| | (a) | (b) |
| Equity compensation plan approved by Securities holders (1) | 2,481,368 | \$ 2.64 |
| Equity compensation plan not approved by Securities holders | -0- | -0- |
| Total | 2,481,368 | \$ 2.64 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

(1) Reflects options to purchase shares of the Company's common stock and shares available for the Company's Stock Option Plan.

8

ITEM 6. SELECTED FINANCIAL DATA.

| | YEARS ENDED SEPTEMBER 30, | | | |
|--|---------------------------------------|------------|------------|------------|
| | 2005 (1) | 2004 (1) | 2003 (1) | 2002 (2) |
| | (IN THOUSANDS, EXCEPT PER SHARE DATA) | | | |
| Revenue | 31,860 | 29,330 | 30,260 | 20,747 |
| Gross margin % | 36% | 58% | 66% | 59% |
| Operating (loss) income | (7,227) | 3,158 | 5,265 | 1,666 |
| Net (loss) income | (7,017) | 1,133 | 3,707 | 901 |
| Average shares outstanding for basic earnings (loss) per share | 15,919,286 | 15,734,470 | 15,495,148 | 15,114,000 |
| Basic earnings (loss) per share | \$ (0.44) | \$ 0.07 | \$ 0.24 | \$ 0.06 |
| Average shares outstanding for diluted earnings (loss) per share | 15,919,286 | 16,469,443 | 16,095,448 | 15,960,000 |
| Diluted earnings (loss) per share | \$ (0.44) | \$ 0.07 | \$ 0.23 | \$ 0.06 |
| Balance Sheet Data: | | | | |
| Working capital | 8,434 | 17,421 | 15,342 | 10,856 |
| Total assets | 26,206 | 33,536 | 29,962 | 23,748 |
| Long-term debt | 630 | 827 | 728 | 693 |
| Stockholders' equity | 13,723 | 21,272 | 17,606 | 13,928 |

(1) As restated, see note 16 to the consolidated financial statements

(2) Not restated, presented as originally reported

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

RESTATEMENT OF FINANCIAL STATEMENTS

As more fully stated in the Explanatory Note following the cover page to this amended report and in Note 16 to the audited consolidated financial statements, the Company is filing this amended report to reflect the restatement of the Company's audited consolidated financial statements for the fiscal years ended September 30, 2005, 2004 and 2003, as well as the notes related thereto in Part II, Item 8 of this Form 10-K/A. The accompanying management's discussion and analysis of the Company's financial condition and results of operations included in this report reflects the impact of the restatement.

FOR THE YEARS ENDED SEPTEMBER 30, 2005 AND 2004 - RESULTS OF OPERATIONS

REVENUE AND GROSS MARGIN

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Revenue for the year ended September 30, 2005 increased \$2.5 million or 9% to \$31.9 million from \$29.3 million in 2004. The U.S. revenues were \$21.8 million or 27% higher than the 2004 revenues of \$17.1 million. The increase in U.S. revenues was fueled by the continuing increase in the demand for the company's TUTOPLAST(R) bone products for dental applications sold by Zimmer Dental ("Dental"), the company's marketing partner. In January 2005, the Company developed, in association with Zimmer Dental, a new bone block to augment ridge restoration. The Dental business increased 100% from a year ago. The spine revenues decreased 37%, primarily due to significant purchases by Zimmer Spine ("Spine") in 2004. The urology business was essentially flat with a decrease of 6% from a year ago as this business is decreasing due to the increased reliance on synthetics for incontinence. However, Mentor continues to do well in the pelvic floor reconstruction market, with a slight increase in revenues for this product line. The Ophthalmic business was essentially flat as this is a mature and niche business.

The International operation had revenues of \$10.1 million, a decrease of \$2.1 million or 17% from the 2004 revenues of \$12.2 million. The decrease in revenues was primarily due to the temporary delay in the renewal of the CE marks ("European Conformity") on certain products, which was resolved at the end of the first quarter of 2005, the resolution of certain regulatory issues in France and the temporary backlog of xenograft product lines.

9

An analysis of revenue follows:

| (\$000's omitted) | FY 2005 | FY 2004 | FY 2003 | 4th Qtr. FY 2005 | 4t FY |
|---------------------|---------|---------|---------|---------------------|----------|
| Dental | 13,785 | 6,893 | 3,720 | 4,115 | |
| Spine | 3,318 | 4,850 | 10,847 | 336 | |
| Urology | 2,633 | 2,809 | 3,880 | 540 | |
| Ophthalmic | 1,505 | 1,553 | 1,352 | 452 | |
| Other | 701 | 1,021 | 1,369 | 137 | |
| Total-U.S. | 21,752 | 17,126 | 21,168 | 5,580 | |
| Germany | 1,980 | 3,521 | 2,624 | 487 | |
| ROW | 6,220 | 6,001 | 4,883 | 1,324 | |
| France | 1,337 | 2,121 | 1,085 | 391 | |
| Other | 571 | 561 | 500 | 170 | |
| Total-International | 10,108 | 12,204 | 9,092 | 2,372 | |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | | |
|--------------------|--------|--------|--------|-------|
| Total Consolidated | 31,860 | 29,330 | 30,260 | 7,952 |
|--------------------|--------|--------|--------|-------|

Gross margins for the year ended September 30, 2005 decreased to 36% from 58% in 2004. The lower margins were due to several factors, 1), an unfavorable mix of lower margin products from the dental product revenues versus the spine revenues. The dental revenues as a percentage of total revenues increased to 43% of total revenues versus 24% a year ago, 2), initial start-up manufacturing costs of \$1.6 million, expensed in the third quarter, associated with shifting production of the dental product lines from Germany to the U.S. The production transfer has been fully completed, 3), the recording in the fourth quarter of \$1.0 million for the inventory reserve impact of the voluntary recall of products during fiscal year 2005, 4), the estimated patient testing and other related expenses of \$250,000 as a result of the product recall recorded in the fourth quarter of fiscal year 2005.

VOLUNTARY RECALL. On October 12, 2005, the Company issued a voluntary recall of all product units which utilized donor tissue received from BioMedical Tissue Services/BioTissue Recovery Services ("BioMedical"). This action was taken because the Company was unable to satisfactorily confirm that BioMedical had properly obtained donor consent. The Company quarantined all BioMedical products in its inventory, having a value of \$1,035,000 and has notified all customers and distributors of record regarding this action. In connection with this recall, the Company has destroyed \$174,000 of inventory and accrued \$861,000 of inventory reserve and \$250,000 of other related costs at September 30, 2005.

GENERAL AND ADMINISTRATIVE

General and administrative expenses increased 29% in 2005 to \$5.4 million from \$4.2 million in 2004. The increase was due to higher compensation costs related to new personnel (\$534,000), expenses related to the closing of the New Jersey Corporate Offices (\$444,000), expenses related to the Sarbanes-Oxley compliance (\$118,000), unfavorable translation of Euro-based expenses (\$84,000), and other expenses (\$26,000). As a result, General and Administrative expenses, as a percentage of revenues, increased from 14% in 2004 to 17% in 2005.

DISTRIBUTION AND MARKETING

Distribution and Marketing expenses were increased 32% or \$2.8 million in 2005 to \$11.5 million from \$8.7 million in 2004. The increase was due mainly to higher marketing fees paid to Dental of \$6.1 million in 2005 versus \$3.2 million a year ago or an increase of \$2.9 million. This is a result of a 100% increase in dental revenues in 2005, from \$6.9 million of revenues in 2004 to \$13.8 million in 2005. As a result, Distribution and Marketing expenses, as a percentage of revenues, increased from 30% in 2004 to 36% in 2005.

RESEARCH AND DEVELOPMENT

Research and Development expenses increased 16% or \$0.3 million in 2005 to \$1.7 million. The increase was due to increased development efforts in the dental and spine product areas. As a percentage of revenues, Research and Development expenses remained at 5% in 2005 and 2004.

LITIGATION CONTINGENCY

In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the original proposed judgment received against the Company by \$406,000 between the Company and a former international distributor. At September 30, 2005 and 2004, the Company continues to maintain an accrual of

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

\$476,000 with respect to the remaining appeal and legal costs. Management believes that such accrual is sufficient and the final settlement will not have a material impact on its results of operations or financial position.

10

OTHER INCOME/EXPENSE

Other expense for 2005 decreased \$505,000 from \$601,000 in 2004 to \$96,000 in 2005. This was primarily the result of lower foreign exchange losses due to the strengthening of the dollar versus the Euro and lower inter-company balances at year-end.

INTEREST EXPENSE

Interest expense in 2005 increased due to borrowings for capital expenditure equipment related to the facility expansion programs in Florida and Germany.

(BENEFIT OF) PROVISION FOR INCOME TAXES

The (benefit of) provision for income taxes is mainly due to the income tax benefit on the loss from the foreign entity. The Company continues to record a full valuation allowance on its U.S. operations.

NET (LOSS) INCOME

As a result of the above, net loss for the year ended September 30, 2005 totaled \$7.0 million, \$0.44 basic and diluted loss per share as compared to a net income of \$1.1 million, \$0.07 basic and diluted earnings per share for 2004. As a percentage of revenues, net income decreased from 3.9% in 2004 to a net loss of 22.0% in 2005.

ACCOUNTS RECEIVABLE

The accounts receivable balance decreased in 2005 by 29% due to an increase in collection efforts resulting in a 16% improvement of the day's sales outstanding from 50 in 2004 to 42 in 2005.

INVENTORY

The inventory balance decreased to \$9.5 million at September 30, 2005 or 33% from \$14.3 million at September 30, 2004. The decrease was primarily due to the successful effort to improve production planning and control and reduce overall inventory levels. Approximately \$1.0 million of the decrease represents inventory written-off due to the voluntary recall of certain products.

FOR THE YEARS ENDED SEPTEMBER 30, 2004 AND 2003 - RESULTS OF OPERATIONS

REVENUE AND COST OF REVENUE

Revenue for the year ended September 30, 2004 decreased \$1.0 million or 3% to \$29.3 million from \$30.3 million in 2003. The US operation revenues were \$17.1 million or 19% lower than the 2003 revenues of \$21.2 million. The decrease in revenue was due to the new arrangement with Zimmer Spine ("Spine"). In April 2003, the Company signed a renegotiated U.S. Distribution Agreement with Centerpulse Spine-Tech, now known as Zimmer Spine, whereby Spine has become a "stocking distributor". The effect of this new arrangement means that Spine has now been invoicing the end customer directly. The new agreement also has eliminated marketing fees paid to Spine included in Distribution and Marketing. The Company's U.S. revenues for the prior year would have been \$17.2 million or

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

\$4.0 million lower under the new agreement with Spine as compared to the U.S. revenues of \$17.1 million for 2004. The Spine business, after considering the new arrangement, decreased by \$2.0 million, which is the direct result of over-buying by Spine at the end of the prior year. This decrease in the Spine business was fully offset by an increase in the demand for the Company's TUTOPLAST processed Puros (TM) Bone Grafting Material for dental applications sold by Zimmer Dental ("Dental"), the Company's marketing partner. This product line contributed an increase in revenue of \$3.2 million from the comparable year.

The International operation had revenues of \$12.2 million or an increase of 24% or \$2.2 million from the 2003 revenues of \$9.1 million. The increase in revenues was positively impacted in the amount of \$1.3 million by currency exchange rates. The balance of the increase in revenues was primarily due to increased penetration of the French market and improved distributor revenues worldwide.

Gross margins for the year ended September 30, 2004 decreased to 58% from 66% in 2003. The slightly lower margins were primarily due to an unfavorable mix of lower margin products from the dental product revenues versus the spine revenues. The Dental revenues as a percentage of total revenues increased to 24% of total revenues versus 12% a year ago. This unfavorable mix was partially offset by improved manufacturing efficiencies.

GENERAL AND ADMINISTRATIVE

General and administrative expenses decreased 6% in 2004 to \$4.2 million from \$4.5 million in 2003. The overall decrease was due primarily to lower compensation costs related to open positions and lower bonus (\$462,000) and reduced bad debt reserves (\$237,000), partially offset by unfavorable foreign exchange variance (\$227,000), merger and acquisition expenses (\$190,000) and other expenses (\$3,000). As a percentage of revenues, General and Administrative expenses remained at 15% in 2004 and 2003.

11

DISTRIBUTION AND MARKETING

Distribution and Marketing expenses were essentially flat decreasing \$0.1 million in 2004 to \$8.7 million from \$8.8 million in 2003. The decrease was primarily due to lower marketing fees as a result of the new agreement with Spine, whereby the Spine marketing fees have been eliminated since May 1, 2003. The Spine marketing fees of \$2.9 million in 2003 were completely eliminated in 2004, while the marketing fees paid to Dental increased from \$1.7 million in 2003 to \$3.2 million in 2004 as a result of increased Dental revenues. The reduction in overall marketing fees of \$1.4 million was offset by unfavorable foreign exchange variance (\$526,000), higher compensation due to the re-building of the direct sales force in Germany and new product managers in the U.S. (\$398,000), product brochures and other marketing expenses (\$175,000), higher travel expenses (\$107,000), office expenses (\$104,000), increased commissions (\$80,000) and other expenses (\$10,000). As a percentage of revenues, Distribution and Marketing expenses increased from 29% in 2003 to 30% in 2004.

RESEARCH AND DEVELOPMENT

Research and Development expenses increased 75% in 2004 to \$1.4 million from \$0.8 million in 2003. The increase was due to increased development efforts in the spine, dental and ligament product areas, which was consistent with management's plans. As a percentage of revenues, Research and Development expenses increased from 3% in 2003 to 5% in 2004.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

LITIGATION CONTINGENCY

In 2003, the Company received a proposed judgment in Germany as the result of a dispute between the Company and a former international distributor. The estimated settlement, including legal costs was accrued as a litigation contingency. In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the original proposed judgment received against the Company by \$406,000. At September 30, 2004 and 2003, the Company accrued \$476,000 and \$836,000, respectively with respect to the remaining appeal and legal costs. Management believes that such accrual is sufficient and the final settlement will not have a material impact on its results of operations or financial position.

OTHER EXPENSE

Other expense for 2004 increased \$233,000 from \$368,000 in 2003 to \$601,000 in 2004. This was primarily the result of higher foreign exchange losses due to the weakness of the dollar versus the Euro.

INTEREST EXPENSE

Interest expense in 2004 increased due to the leasing of capital expenditure equipment.

PROVISION FOR INCOME TAXES

The provision for income taxes is solely due to the foreign entity being taxed. The Company continues to record a full valuation allowance on its U.S. operations.

NET INCOME

As a result of the above, net income for the year ended September 30, 2004 totaled \$1.1 million, \$0.07 basic and diluted earnings per share as compared to a net income of \$3.7 million, \$0.24 basic and \$0.23 diluted earnings per share for 2003. As a percentage of revenues, net income decreased from 12.2% in 2003 to 3.9% in 2004.

ACCOUNTS RECEIVABLE

The accounts receivable balance decreased in 2004 by 11% due to an increase in collection efforts resulting in a 32% improvement of the day's sales outstanding from 71 in 2003 to 50 in 2004.

INVENTORY

The inventory balance increased to \$14.3 million at September 30, 2004 or 24% from \$11.5 million at September 30, 2003. This increase was partially due to a 12% weakening of the dollar against the Euro. The higher inventory also reflects the meeting of contractual commitments in terms of safety stock with its two major marketing partners, Spine and Dental and the building of inventory associated with the introduction of two new product lines for dental applications.

CRITICAL ACCOUNTING POLICIES

The Company's significant accounting policies are more fully described in Note 2 to the consolidated financial statements. However, certain of the accounting policies are particularly important to the portrayal of the financial position and results of operations and require the application of significant judgment by management; as a result, they are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on historical experience, terms of existing contracts, observance of trends in the industry, information provided by customers and information available from other outside sources, as appropriate. The Company's significant accounting policies include:

12

INVENTORIES. Inventories are valued at the lower of cost (weighted average basis) or market. Work in process and finished goods includes costs attributable to direct labor and overhead. Reserves for slow moving and obsolete inventories are provided based on historical experience, current product demand and the remaining shelf life. The adequacy of these reserves is evaluated quarterly.

REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE. Revenue on product sales is recognized when persuasive evidence of an arrangement exists, the price is fixed and final, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Oral or written purchase authorizations are generally obtained from customers for a specified amount of product at a specified price. Title transfers at the time of shipment. Customers are provided with a limited right of return. Revenue is recognized at shipment. Reasonable and reliable estimates of product returns are made in accordance with SFAS No. 48 and allowances for doubtful accounts based on significant historical experience. Revenue from service sales is recognized when the service procedures have been completed or applicable milestones have been achieved. Revenue from distribution fees includes nonrefundable payments received as a result of exclusive distribution agreements between the Company and independent distributors. Distribution fees under these arrangements are recognized as revenue as products are delivered.

FOREIGN CURRENCY TRANSLATION. The functional currency of the Company's German subsidiary is the Euro for the years 2005, 2004 and 2003. Assets and liabilities of foreign subsidiaries are translated at the period end exchange rate while revenues and expenses are translated at the average exchange rate for the year. The resulting translation adjustments, representing unrealized, non-cash losses are made directly to comprehensive income. Gains and losses resulting from transactions between the Company and its subsidiaries, which are made in currencies different from their own, are included in income as they occur. The Company recognized currency losses of \$173,000, \$700,000 and \$350,000 in 2005, 2004 and 2003, respectively.

VALUATION OF DEFERRED TAX ASSET. We record valuation allowances to reduce the deferred tax assets to the amounts estimated to be recognized. While we consider taxable income in assessing the need for a valuation allowance, in the event we determine it is more likely than not that we would be able to realize our deferred tax assets in the future, an adjustment would be made and income increased in the period of such determination. Likewise, in the event we determine we would not be able to realize all or part of our deferred tax assets in the future, an adjustment would be made and charged to income in the period of such determination. We recorded a deferred tax asset valuation allowance of \$6,309 and \$4,523 at September 30, 2005 and 2004, respectively, representing 100% of existing U.S. deferred tax assets.

CONCENTRATION OF CREDIT RISK

The exposure to risk related to foreign currency exchange is limited primarily to inter-company transactions. The Company currently does not utilize forward exchange contracts or any other type of hedging instruments.

The Company's principal concentration of credit risk consists of trade

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

receivables. Distribution of products and revenues is provided through a broad base of independent distributors. Two customers accounted for 18% of consolidated revenue in 2005 while the same two customers accounted for 22% of consolidated revenue in 2004 and 30% in 2003. The Company does not believe that this concentration of sales and credit risks represents a material risk of loss with respect to the financial position as of September 30, 2005 and 2004.

LIQUIDITY AND CAPITAL RESOURCES

At September 30, 2005 and 2004 the Company had working capital of \$8.4 million and \$17.5 million, respectively, a decrease of 52%. In the past, the Company has relied upon its available working capital lines and institutional investors to fund operational cash flow, when needed. This decrease is primarily due to a concerted effort to reduce inventory levels by \$4.7 million and an improvement in the accounts receivable DSO (days sales outstanding) from 50 to 42 or \$1.5 million, partially offset by an increase in short-term borrowing of \$1.0 million.

Net cash decreased from \$5.0 million in 2004 to \$3.6 million in 2005 primarily as the result of the effect of the net loss in 2005 of \$7.0 million versus a net income of \$1.1 million in 2004. The decrease in cash due to the net loss in 2005 was partially offset by significant reductions in inventory levels and accounts receivable balances as aforementioned above. Net cash used in operating activities was \$560,000 in 2005 compared to net cash provided from operating activities of \$380,000 in 2004. The decrease resulted primarily from the decrease in net income partially offset by the reductions in inventory and accounts receivable.

Net cash used in investing activities, representing purchases of capital expenditures, was \$1,681,000 in 2005 and \$1,759,000 in 2004. The continued spending on capital expenditure is due to the facility expansion in the Florida and German manufacturing locations and replacement manufacturing equipment.

Net cash from financing activities in 2005 and 2004 of \$981,000 and \$496,000 relates primarily to the proceeds from revolving credit arrangements to finance the expansion program in Germany, partially offset by the repayments of long-term debt.

The Company's future minimum commitments and obligations under current operating leases for its offices and manufacturing facilities in the U.S. and Germany, as well as several leases related to office equipment and automobiles through 2009 total \$3,340,000. The Company considers these commitments and obligations to be reasonable in order to maintain the current and future business requirements.

13

The following table summarizes the Company's contractual obligations as of September 30, 2005:

| (In thousands) | Total | 2006 | 2007 | 2008 | 2009 |
|---------------------------------|----------|----------|--------|--------|--------|
| Long-term debt (1) | \$ 814 | \$ 184 | \$ 197 | \$ 433 | \$ 0 |
| Operating lease obligations (1) | \$ 3,340 | \$ 1,064 | \$ 787 | \$ 632 | \$ 557 |
| Short-term borrowings (1) | \$ 1,048 | \$ 1,048 | | | |
| (1) Does not include interest | | | | | |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

The Company maintains current working capital credit lines totaling 1.5 million euros (approximately \$1.8 million) with three German banks and a \$1.0 million credit line with a U.S. bank. At September 30, 2005 the Company had no borrowings against these lines. There are no covenants on the credit lines and senior and equipment debt. The Company's ability to generate positive operational cash flow is dependent upon increasing processing revenue through increased recoveries by tissue banks in the U.S. and Europe, and the development of additional markets and surgical applications for its products worldwide. While the Company believes that it continues to make progress in both these areas, there can be no assurances that changing governmental regulations will not have a material adverse effect on results of operations or cash flow.

The Company may seek additional financing to meet the needs of its long-term strategic plan. The Company can provide no assurance that such additional financing will be available, or if available, that such funds will be available on favorable terms.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

In the United States and in Germany the Company is exposed to interest rate risk. Changes in interest rates affect interest income earned on cash and cash equivalents and interest expense on revolving credit arrangements. The Company does not enter into derivative transactions related to cash and cash equivalents or debt. Accordingly, we are subject to changes in interest rates. Based on September 30, 2005 cash and cash equivalents and long-term debt, a 1% change in interest rates would have a negligible impact on our results of operations.

The value of the U.S. dollar affects our financial results. Changes in exchange rates may positively or negatively affect revenues, gross margins, operating expenses and net income. The Company does not maintain hedging programs to mitigate the potential exposures of exchange rate risk. Accordingly, the results of operations are adversely affected by the weakening of the U.S. dollar against the Euro, since certain products are manufactured and imported from the Company's wholly owned subsidiary in Germany. Because of the foregoing factors, as well as other variables affecting the operating results, past financial performance should not be considered a reliable indicator of future performance.

ITEM 8. FINANCIAL STATEMENTS.

The information required by this Item is found immediately following the signature page of this Report.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

DISCLOSURE CONTROLS AND PROCEDURE

In the Form 10-K for the Company's fiscal year ended September 30, 2005, initially filed with the SEC on December 22, 2005, the Company's management, with the participation of the Company's chief executive officer and former chief financial officer, evaluated the Company's disclosure controls and procedures (as defined in Rule 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934, as amended (the "34 Act")) as of September 30, 2005 (the "Evaluation Date"). Based on that evaluation, the chief executive officer and former chief financial officer of the Company concluded that, as of the Evaluation Date, the disclosure controls and procedures established by the Company were adequate to ensure that information required to be disclosed by the Company in reports that the Company files under the Exchange Act, is recorded, processed, summarized and reported on a timely basis in accordance with applicable rules and regulations.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Subsequent to that filing (and as part of the financial review for the three and six months ended March 31, 2006), under the direction of the Company's chief executive officer and new chief financial officer, the Company conducted an analysis of the Company's inventory on hand as of prior reporting periods, its policies and procedures over certain journal entries recorded in the financial close process, and the effectiveness of the design and operation of the Company's disclosure controls and procedures, (as defined in Rule 13(a) - 15(e) under the 34 Act). The evaluation led the Company to conclude that as of September 30, 2005, the Company's controls and procedures relating to the calculation of intercompany profit and certain journal entries recorded in the financial close process were deficient, resulting in a material weakness in internal control over financial reporting. Accordingly, the Company concluded that as of September 30, 2005 our disclosure controls and procedures were not effective in ensuring that information required to be disclosed by us in the reports that we file under the Securities and Exchange Act is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission rules and forms.

As a result, the Company has restated its financial statements for the periods covered in the Company's annual report on Form 10-K/A for the fiscal year ended September 30, 2005 (see Note 16 to the accompanying audited Consolidated Financial Statements).

A material weakness in internal control is a significant deficiency or combination of significant deficiencies that results in more than a remote likelihood that a material misstatement of the financial statements would not be prevented or detected on a timely basis by the Company. The

14

Company has subsequently taken steps to remediate this material weakness including designing and implementing a more effective and precise analytic model for calculating intercompany profit. Additionally, the Company has developed a system for assuring the accuracy of this model. This system includes an enhanced reporting process for determining actual costs and transfer prices used in the calculation of intercompany profit to be eliminated during the consolidation process. Also, the Company has designed and documented new policies and procedures to strengthen its controls over certain journal entries recorded in its financial close process.

Management believes that these subsequent changes in the design of internal controls will strengthen the Company's disclosure controls and procedures, as well as its internal control over financial reporting, and will remediate the material weakness that the Company identified in its internal control over financial reporting as of September 30, 2005. The Company has discussed this material weakness and its remediation program with our Audit Committee. The Company recognizes that controls and procedures can provide only reasonable assurance of achieving the desired control objectives. Accordingly, the Company intends to continue to refine its internal control over financial reporting on an ongoing basis as it deems appropriate.

The Company instituted the changes noted above during its financial close process during the quarter ended March 31, 2006 to materially enhance its internal control over financial reporting of inventory, net revenues, cost of revenues and financial close process.

CHANGES IN CONTROL:

Except as described above, there has not been any change in our internal

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

control over financial reporting during the quarter ended September 30, 2005 that has materially affected, or is reasonably likely to materially affect, those controls.

ITEM 9B. OTHER INFORMATION.

None.

15

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.

The following table sets forth the names and ages of the directors and executive officers of the Company (each, a "Director" and/or "Officer"), the positions and offices that each Director and Officer held with the Company, and the period during which each served in such positions and offices. Each Director serves for a term of one (1) year, until his successor is duly elected and qualified.

| NAME | AGE | POSITIONS/OFFICES | PERIOD SERVED IN OFFICE/POSITION |
|-----------------------------|-----|---|--|
| G. Russell Cleveland | 67 | Director | 1997 - present |
| Roy D. Crowninshield, Ph.D. | 57 | Chairman of the Board Director Interim CEO | July 2004 - present 2003 - present July 2004 - December 2004 |
| Neal B. Freeman | 65 | Director | June 2005 - present |
| J. Harold Helderman, MD | 60 | Director | 1997 - present |
| Udo Henseler, PH.D. | 65 | Director | June 2005 - present |
| Manfred K. Kruger | 59 | President, International President Chief Executive Officer Chief Operating Officer Director | January 2005 - present July 1999 - December 1999 December 1999 - January 2005 July 1999 - December 1999 June 1997 - March 1999 |
| George Lombardi | 62 | Chief Financial Officer, Treasurer and Secretary | 1998 - present |
| Guy L. Mayer | 54 | Chief Executive Officer Director | January 2005 - present January 2005 - present |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | |
|--------------------------|----|----------|---------------------|
| Adrian J. R. Smith | 61 | Director | June 2005 - present |
| Carlton E. Turner, Ph.D. | 65 | Director | 2000 - present |

The following is a summary of the business experience of each of the Company's Officers and Directors listed in the above-referenced table, and of certain other significant employees of the Company, during the past five (5) years.

16

OFFICERS AND DIRECTORS

G. RUSSELL CLEVELAND is the President, Chief Executive Officer, sole Director, and majority shareholder of Renaissance Capital Group, Inc. ("Renaissance"). He is also President, Chief Executive Officer, and a director of Renaissance Capital Growth & Income Fund III, Inc. Mr. Cleveland is a Chartered Financial Analyst with more than thirty-five (35) years experience as a specialist in investments for smaller capitalization companies. A graduate of the Wharton School of Business, Mr. Cleveland has served as President of the Dallas Association of Investment Analysts. Mr. Cleveland currently serves on the Boards of Directors of Renaissance U.S. Growth & Income Trust PLC, Cover-All Technologies, Inc., Digital Recorders, Inc., Integrated Security Systems, Inc., and Camino-Soft, Inc. and Precis, Inc.

ROY D. CROWNINSHIELD, PH.D. is the current Chairman of the Board. From July 2004 to December 2004, Dr. Crowninshield was the Interim Chief Executive Officer of the Company. Prior to joining Tutogen, Dr. Crowninshield served twenty-one (21) years in various capacities at Zimmer Holdings, Inc., including President of Zimmer's U.S. operations and most recently as the Company's Chief Scientific Officer. Prior to joining Zimmer, Inc. in 1983, he was a faculty member at the University of Iowa where he led many research projects evaluating the function of total joint implants. He currently holds academic appointments as a professor in the Orthopedic Surgery Department at Rush Medical College in Chicago, Illinois and as an adjunct professor in the College of Engineering of the University of Notre Dame. He holds undergraduate and doctorate degrees from the University of Vermont. He has worked in the orthopedic industry for over twenty (20) years and has extensive experience in the research and development, manufacture, and clinical investigation of orthopedic implants. He has authored more than 100 journal articles, book chapters, and published abstracts in orthopedics and engineering.

NEAL B. FREEMAN is the Chairman and CEO of The Blackwell Corporation (since 1981), an advisory firm, with clients in the communications, defense and wealth management industries. He is also Chairman of the Foundation Management Institute; Chairman of the Board of Advisors of the investment advisory firm, Train Babcock Advisors and Director of North American Management Corp.

J. HAROLD HELDERMAN, MD is Dean of Admissions and Professor of Medicine, Microbiology and Immunology, since 1999, at Vanderbilt University, Nashville, Tennessee, and is the Medical Director of the Vanderbilt Transplant Center since 1989. Dr. Helderman received his MD from the State University of New York, Downstate Medical Center in 1971, Summa Cum Laude. In addition to book and monograph writings, he has authored more than 125 publications in his field of transplant medicine. Dr. Helderman is past President of the American Society of Transplantation.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

UDO HENSELER, PH.D., is presently acting as the principal/owner of MSI Management Services International (first activated 1994) and serves currently on the Board of Directors of the public companies of eGene, Inc., Spire Corporation and Tutogen Medical, Inc. From 2002 to July 2005 Dr. Henseler was CEO, Director and Chairman of eGene, Inc., a public biotechnology company. From 1999 to June 2002, Dr. Henseler was a Director and from June 2001 to March 2002, he was the Executive Vice President, Director and CFO of ChemoKine Therapeutics Corporation. From 2000 to June 2001, he was the Senior Vice President and CFO of Isotag Technology, Inc., a biotechnology Company. Dr. Henseler has extensive global public company leadership experience with approximately 40 years of combined service as: VP and CFO of the biotechnology Qualicon Inc., a DuPont company; Director, Senior VP and CFO of the Pharmaceutical Andrx Inc.; VP and CFO of Genetic Systems Corp.; Chair Executive Committee, VP and CFO of Coulter Corporation (life Sciences); group Finance Chief at Beckman, Inc. (life-sciences). Dr. Henseler earned his B.A. in Germany, and Master's and Ph.D. degrees from the Claremont Graduate University in Claremont, California. Dr. Henseler is also a Certified Public Accountant.

MANFRED K. KRUGER is the Company's President, International Operations. He joined the Company in June 1997 as General Manager of the Company's German subsidiary. In that capacity, he was responsible for all scientific research and development, production, and distribution and sales. In February 1999, he became Chief Operating Officer and a member of the Company's Board of Directors. On July 1, 1999 he was appointed President of the Company. Prior to joining the Company, Mr. Kruger was Executive Vice President of Fresenius Critical Care International, a division of Fresenius Medical Care, AG. Prior to Fresenius, Mr. Kruger held management positions with Squibb Medical Systems and American Hospital Supply.

GEORGE LOMBARDI is the Company's Chief Financial Officer, Treasurer and Secretary. He joined the Company in March 1998. Mr. Lombardi was the Vice President, Chief Financial Officer of Sheffield Pharmaceuticals, Inc., a publicly held (AMEX) development stage pharmaceutical/biotech Company. Before that, he was the CFO and Director of Fidelity Medical, Inc. and a Senior Financial Executive for the New Jersey and New England Operations of National Health Laboratories, Inc. Prior to this, Mr. Lombardi held Senior Financial positions at the Boehringer Ingelheim Pharmaceutical Company and the Revlon Healthcare Group in New York. Mr. Lombardi is a CPA certified in the state of New Jersey and has a degree in accounting from Fairleigh Dickinson University.

GUY MAYER is the Company's CEO. Prior to Tutogen, Guy served as Chairman and CEO of Visen Medical (from 2003 to 2004), a private Biotech company focused on Molecular Imaging technologies and prior to Visen (from 2000 to 2003), as President and CEO of ETEX Corporation, a private biomedical company based in Cambridge, MA. For 13 years prior to joining ETEX, Mr. Mayer held various senior positions at Zimmer Inc., then a division of Bristol Myers Squibb, with sales in excess of \$1.2 billion. Mr. Mayer's positions at Zimmer included President Global Products Group, President Orthopedics Implant division, President Zimmer Japan and Sr. Vice President Zimmer International. Prior experience includes general management positions with Picker International in diagnostic imaging, and American Hospital Supply Corporation. Guy is a 1974 Graduate of the University of Ottawa and currently serves on the Board of Directors of several public and private companies.

MR. ADRIAN J.R. SMITH, a member of the audit committee, is CEO of The Woolton Group, since 1997, and a Non-Executive Director of Carter & Carter Group plc, since 2002, a UK company providing learning solutions and outsource services to large corporate organizations. His business career includes 13 years in the professional services industry and 26 years with two Fortune 500 companies. He has been a Global Managing Partner, Marketing & Communication at Deloitte & Touche, the CEO of Grant Thornton LLP, and a Managing Partner at Arthur Andersen

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

in the early to

17

mid-1990's. He held senior international management roles with Ecolab Inc. and also with Procter & Gamble. He serves on the board of Harbor Branch Oceanographic Institution, and the Education Foundation of Indian River County in Florida.

CARLTON E. TURNER, PH.D., D.SC. has been the President and Chief Executive Officer of Carrington Laboratories, Inc. ("Carrington") (NASDAQ: CARN) since April 1995. Carrington is a research-based pharmaceutical and medical device company in the field of wound care products. Dr. Turner has also served as the Chief Operating Officer from November 1994 to April 1995 and as the Executive Vice President of Scientific Affairs from January 1994 to November 1994 at Carrington. Before that, he was the President, Chief Operating Officer and Founder of Princeton Diagnostic Laboratories of America from 1987 to 1993. From 1981 to 1987 he was an Assistant to President Ronald Reagan with Cabinet Rank and Director of the White House Drug Policy Office. Previously, he was a Research Professor and Director of the Research Institute of Pharmacological Science, University of Mississippi.

COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934

The Company believes that the reporting requirements, under Section 16(a) of the Exchange Act, for all its executive officers, directors, and each person who is the beneficial owner of more than 10% of the common stock of a company were satisfied except for the following: Mr. Guy Mayer who filed one late Form 4 Report relating to one transaction. Mr. Roy Crowninsheild who filed two late Form 4 Reports relating to two transactions and Mr. Carlton Turner who filed two late Form 4 Reports relating to two transactions.

COMMITTEES OF THE BOARD OF DIRECTORS

Compensation Committee. The Compensation Committee is composed of Dr. Helderman, Dr. Turner and Mr. Freeman, and is chaired by Dr. Turner. This Committee approves, administers and interprets our compensation and benefit policies, including our executive bonus programs. It reviews and makes recommendations to our board of directors to ensure that our compensation and benefit policies are consistent with our compensation philosophy and corporate governance principles. This Committee is also responsible for establishing our CEO's compensation.

Audit Committee. The Audit Committee is composed of Messrs. Cleveland, Smith and Dr. Henseler and is chaired by Mr. Cleveland. This Committee has general responsibility for the oversight and surveillance of our accounting, reporting and financial control practices. Among other functions, the Committee retains our independent public accountants. Each member of the Committee is a non-management director. All members of the Audit Committee are considered to be "financial experts" within the definition of that term under the regulations of the Securities Act.

Nominating Committee. The Nominating Committee is composed of Messrs Smith, Freeman, Dr. Helderman, and Dr. Henseler and is chaired by Dr. Helderman. This committee nominates directors for election by the board or by stockholders and nominates directors for membership on the committees of the board.

ITEM 11. EXECUTIVE COMPENSATION.

COMPENSATION OF DIRECTORS

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

The Company's outside Directors each receive a \$6,000 annual retainer, \$1,500 per in-person attendance at Board and Committee meetings, \$500 per telephonic meetings, plus reimbursement of out-of-pocket expenses.

18

COMPENSATION OF EXECUTIVE OFFICERS

The following table sets forth the compensation awarded to, or paid to all persons who have served as Chief Executive Officer and other officers or individuals whose compensation exceeded \$100,000 for this period.

| Name And Principal Position | Fiscal Year | Annual Compensation | | | Long Term Compensation | |
|---|-------------|---------------------|------------|--------------------------------|--------------------------------|-----------------------------------|
| | | Salary (\$) | Bonus (\$) | Other Annual Compensation (\$) | Restricted Stock Award(s) (\$) | Securities Underlying Options (#) |
| Guy L. Mayer (2) Chief Executive Officer | 2005 | 225,000 | 24,300 | 0 | 0 | 300,000 |
| Roy D. Crowninshield (2) Chief Executive Officer | 2005 | 21,000 | 0 | 0 | 0 | 0 |
| | 2004 | 21,000 | 0 | 0 | 0 | 100,000 |
| Manfred K. Kruger President, International Operations | 2005 | 391,000 | 34,700 | 0 | 0 | 0 |
| | 2004 | 428,550 | 0 | 0 | 0 | 0 |
| | 2003 | 352,500 | 179,700 | 0 | 0 | 37,500 |
| George Lombardi Chief Financial Officer Treasurer and Secretary | 2005 | 166,500 | 20,500 | 0 | 0 | 0 |
| | 2004 | 166,500 | 0 | 0 | 0 | 0 |
| | 2003 | 160,125 | 67,500 | 0 | 0 | 20,000 |
| Dr. Karl Koschatzky Vice President of R & D Worldwide | 2005 | 148,700 | 13,100 | 0 | 0 | 0 |
| | 2004 | 140,000 | 0 | 0 | 0 | 0 |
| | 2003 | 107,600 | 32,400 | 0 | 0 | 45,000 |

- (1) Includes pension and automobile leasing and other automobile related expenses.
- (2) Dr. Crowninshield was appointed Chairman and interim Chief Executive Officer on July 1, 2004. As CEO of the Company, Dr. Crowninshield devoted at least one-third of his time on Company affairs for which he was compensated at the rate of \$7,000 per month and was granted options to purchase 100,000 shares of the Company's common stock. Dr. Crowninshield resigned as the interim Chief Executive Officer on December 31, 2005, but retained his current position as Chairman of the Company. Dr. Crowninshield

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

was replaced by Mr. Mayer on January 1, 2005.

EMPLOYMENT AGREEMENTS

On December 6, 2004, the Company entered into an employment agreement with Mr. Guy W. Mayer to serve as Chief Executive Officer (CEO) of the Company, commencing January 1, 2005. The term of employment is indefinite and terminates upon written notice by the Company, notice of termination by Mr. Mayer or termination of employment for cause. Minimum notice of termination by the Company, except for cause, is one (1) year from the end of any calendar quarter. Mr. Mayer's current annual base salary is \$315,000. In addition, the employment agreement provides for a bonus for the balance of the Company's fiscal year 2005 in an amount up to 90% of his earned salary for fiscal 2005, subject to the Company realizing certain performance goals based on revenue and operating income. In addition, Mr. Mayer was granted a ten (10) year option, upon commencement of employment, to purchase 250,000 shares of the Company's common stock, exercisable at the market price on the date of grant, 25% on the date of grant and 25% on each of the first three (3) anniversaries.

The Company has an employment agreement with Manfred Kruger, its President, International Operations. Pursuant to that agreement, the term of Mr. Kruger's employment with the Company commenced on June 16, 1997. The agreement is for an indefinite period and shall terminate upon written notice by the Company, notice of his election to terminate, or the Company terminates his employment for cause. Minimum notice of termination by the Company, except for cause, is one year from the end of a calendar quarter. Mr. Kruger's annual base salary commencing April 1, 2005 is currently \$320,000. In addition, the employment agreement provides for an annual bonus in an amount up to 35% of his annual base salary, subject to the satisfaction of reasonable performance goals established by the board. In addition, Mr. Kruger has a "change of control" agreement whereby he is entitled to 12 months salary in the event he is terminated as the result of a change of control of the Company.

19

The Company has a severance agreement with George Lombardi, its Chief Financial Officer, Treasurer and Secretary. Pursuant to that agreement, upon written notice of his termination at least six weeks before a calendar quarter, the Company will provide six months salary including medical and 401(K) benefits. Mr. Lombardi's annual base salary is currently \$166,500. The Company also provides an annual bonus in an amount up to 30% of his annual base salary, subject to the satisfaction of reasonable performance goals established by the board. In addition, Mr. Lombardi has a "change of control" agreement whereby he is entitled to 12 months salary including medical benefits in the event he is terminated as the result of a change of control of the Company.

STOCK OPTION PLANS

The Company has a 1996 Incentive and Non-Statutory Stock Option Plan (the "1996 Plan") to attract, maintain and develop management by encouraging ownership of the Company's Common Stock by Directors, Officers and other key employees. The following is a summary of the provisions of the 1996 Plan. This summary is qualified in its entirety by reference to the 1996 Plan, a copy of which may be obtained from the Company.

The 1996 Plan authorizes the granting of both incentive stock options, as defined under Section 422 of the Internal Revenue Code of 1986 ("ISO"), and non-statutory stock options ("NSSO") to purchase Common Stock. All employees of the Company and its affiliates are eligible to participate in the 1996 Plan. The 1996 Plan also authorizes the granting of NSSOs to non-employee Directors and

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

consultants of the Company. Pursuant to the 1996 Plan, an option to purchase 10,000 shares of Common Stock shall be granted automatically to each outside Director who is newly elected to the Board. In addition, an option to purchase 2,500 shares of Common Stock shall be granted automatically, on the date of each annual meeting of shareholders of the Company, to each outside Director who has served in that capacity for the past six months and continues to serve following such meeting. Any outside Director may decline to accept any option granted to him under the 1996 Plan.

The Board of Directors or the Compensation and Stock Option Committee is responsible for the administration of the 1996 Plan and determines the employees to which options will be granted, the period during which each option will be exercisable, the exercise price, the number of shares of the Common Stock covered by each option, and whether an option will be a non-qualified or an incentive stock option. The exercise price, however, for the purchase of shares subject to such an option, cannot be less than 100% of the fair market value of the Common Stock on the date the option is granted. The Stock Option Committee has no authority to administer or interpret the provisions of the 1996 Plan relating to the grant of options to outside Directors. The current members of the Compensation and Stock Option committee are Dr. Turner, Dr. Helderman and Mr. Freeman.

No option granted pursuant to the 1996 Plan is transferable otherwise than by will or the laws of descent and distribution. The term of each option granted to an employee under the 1996 Plan is determined by the Board of Directors or the Compensation and Stock Option Committee, but in no event may such term exceed ten (10) years from the date of grant. Each option granted to an outside Director under the 1996 Plan shall be exercisable in whole or in part during the four (4) year period commencing on the date of the grant of such option. Any option granted to an outside Director should remain effective during the entire term, regardless of whether such Director continues to serve as a Director. The purchase price per share of Common Stock under each option granted to a Director will be the fair market value of such share on the date of grant.

The vesting period for options granted under the 1996 Plan are set forth in an option agreement entered into with the optionee. Options granted to an optionee terminate three (3) years after retirement. In the event of death or disability, all vested options expire one (1) year from the date of death or termination of employment due to disability and unvested options are forfeited. Upon the occurrence of a "change in control" of the Company, the maturity of all options then outstanding under the 1996 Plan will be accelerated automatically, so that all such options will become exercisable in full with respect to all shares that have not been previously exercised or become exercisable. A "change in control" includes certain mergers, consolidation, and reorganization, sales of assets, or dissolution of the Company.

The 1996 Plan presently reserves 4,000,000 shares of the Company's Common Stock for issuance thereunder. As of September 30, 2005, options have been issued for 3,451,697 shares and 548,303 shares remain available under the 1996 Plan. Unless sooner terminated, the 1996 Plan will expire on February 27, 2006.

OPTIONS GRANTED IN FISCAL YEAR 2005

The following table provides information as to options granted to the Company's Chief Executive Officer during the fiscal year ended September 30, 2005. All such options were granted under the Company's 1996 Stock Option Plan.

| Number of Securities | Percent of |
|-------------------------|------------|
|-------------------------|------------|

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | Underlying Options Granted (#) | Total Options Granted To Employees | Exercise or Base Price (\$/Sh) | Expiration Date | St |
|--------------|--------------------------------------|--|--------------------------------------|--------------------|----|
| | 250,000 | 40.2% | \$ 2.60 | January 3, 2015 | \$ |
| Guy L. Mayer | 50,000 | 8.0% | \$ 4.17 | September 26, 2015 | \$ |

20

(1) Potential realizable value is based on the assumption that the Common Stock appreciates at the annual rate shown (compounded annually) from the due date of grant until the expiration of the option term. These numbers are calculated based on the requirements of the SEC and do not reflect the Company's estimate of future price growth.

The following table sets forth the value of the unexercised options at September 30, 2005. No options were exercised during this fiscal year. The market price of the Company's common stock at September 30, 2005 was \$4.56.

AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FY-END OPTION VALUES

| Name | Number of Unexercised Options at September 30, 2005 | | Value of Unexercised In-the-Money Options at September 30, 2005 | |
|---------------------|---|---------------|---|---------------|
| | Exercisable | Unexercisable | Exercisable | Unexercisable |
| Guy L. Mayer | 75,000 | 225,000 | \$ 127,375 | \$ 382,125 |
| Manfred K. Kruger | 590,625 | 9,375 | \$ 1,363,600 | \$ 12,094 |
| George Lombardi | 213,000 | 5,000 | \$ 542,475 | \$ 9,450 |
| Dr. Karl Koschatzky | 104,168 | 22,500 | \$ 258,087 | \$ 28,350 |

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

The Compensation Committee consists of Dr. Turner, Dr. Helderman and Mr. Freeman. There are no "interlocks" as defined by the SEC with respect to any member of the committee.

COMPENSATION COMMITTEE REPORT

The following Report of the Compensation Committee and the information under the heading Performance Graph below shall not be deemed incorporated by reference by any general statement incorporating by reference into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934 together, the "Acts"), except to the extent that the Company specifically incorporates the information by reference, and shall not otherwise be deemed filed under the Acts.

The Compensation Committee oversees the Company's compensation program. The goals of the Company's compensation program are to attract, retain, motivate and reward highly qualified management personnel and to provide them with long-term career opportunities. The Company's compensation philosophy is to provide its executives with a competitive total compensation package which motivates superior job performance, the achievement of the Company's business objectives, and the enhancement of shareholder value.

Compensation of the Company's executive officers is reviewed annually by the

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Board of Directors and the Compensation Committee. Changes proposed for these employees are evaluated and approved by the Compensation Committee on an individual basis. The Company's general approach to compensating executive officers is to pay cash salaries which generally are competitive within ranges of salaries paid to executives of other similar companies, although the Company does not attempt to meet salary levels of such companies. Instead, the Committee sets overall compensation at a level it believes to be fair, based upon a subjective analysis of the individual executive's experience and past and potential contributions to the Company. The Committee also establishes bonus goals for executive officers so as to compensate them on a performance basis. To assist in determining appropriate overall compensation, the Compensation Committee also reviews information regarding the Company's revenues and income.

Stock option grants to employees of the Company, including the Chief Executive Officer, are made at the discretion of the Compensation Committee pursuant to the Company's 1996 Stock Option Plan. Factors and criteria to be used by the Committee in the award of stock options include individual responsibilities, individual performance and direct and indirect contributions to the profitability performance and direct and indirect contributions to the profitability of the Company.

Respectfully submitted, The Compensation Committee

Dr. Carlton E. Turner, Chairman Dr. J. Harold Helderman Neal B. Freeman

PERFORMANCE GRAPH

The following graph shows a comparison of cumulative five (5) year total stockholder returns for the Company's Common Stock, with the cumulative return of the Nasdaq Stock Market - U.S. Index and an industry peer group. The industry peer group of companies selected by the Company is made up of the Company's publicly held competitors in the Medical Device industry. The graph assumes the investment of \$100 on August 17, 2000, the date on which trading commenced on the American Stock Exchange. The comparisons reflect in the table and graph, however, are not intended to forecast the future performance of the Common Stock and may not be indicative of such future performance.

21

COMPARE 5-YEAR CUMULATIVE TOTAL RETURN
AMONG TUTOGEN MEDICAL INC.,
AMEX MARKET INDEX AND PEER GROUP INDEX

[PERFORMANCE GRAPH]

ASSUMES \$100 INVESTED ON SEPT. 30, 2000
ASSUMES DIVIDEND REINVESTED
FISCAL YEAR ENDING SEPT. 30, 2005

COMPARISON OF CUMULATIVE TOTAL RETURN OF ONE OR MORE
COMPANIES, PEER GROUPS, INDUSTRY INDEXES AND/OR BROAD MARKETS

| COMPANY/INDEX/MARKET | FISCAL YEAR ENDING | | | | | |
|----------------------|--------------------|---------|---------|---------|---------|---------|
| | 9/30/00 | 9/30/01 | 9/30/02 | 9/30/03 | 9/30/04 | 9/30/05 |
| TUTOGEN MEDICAL INC | 100.00 | 40.85 | 48.34 | 86.81 | 50.89 | 77.62 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | | | | |
|-----------------------|--------|-------|-------|--------|--------|--------|
| NASDAQ MEDICAL DEVICE | 100.00 | 97.71 | 91.18 | 123.43 | 143.36 | 162.71 |
| AMEX MARKET INDEX | 100.00 | 74.98 | 81.46 | 100.67 | 116.21 | 140.67 |

22

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table sets forth certain information regarding the beneficial ownership of the Company's Common Stock as of November 30, 2005, by (i) each person known to the Company to own beneficially more than 5% of its Common Stock, (ii) each director and executive officer of the Company, and (iii) all directors and executive officers as a group. As of November 30, 2005, there were approximately 15,950,460 shares of Common Stock issued and outstanding.

| NAME AND ADDRESS OF BENEFICIAL OWNER | AMOUNT AND NATURE OF BENEFICIAL OWNER (1) (2) | PERCENTAGE OF CLASS |
|---|--|------------------------|
| SPV 1996 LP 101 Finsbury Pavement London, England EC2A 1EJ | 1,896,794 | 11.90 |
| Zimmer CEP (formerly Centerpulse) USA Holding Co Subsidiary of Zimmer Holdings, Inc. 345 East Main Street Warsaw, IN 46580 | 5,297,124 | 33.25 |
| G. Russell Cleveland (4) | 99,800 | * |
| Roy D. Crowninshield (5) | 47,500 | * |
| Neal B. Freeman (7) | 20,000 | * |
| Dr. J. Harold Helderman (8) | 102,500 | * |
| Udo Henseler, Ph.D (6) | 10,000 | * |
| Dr. Karl Koschatsky (6) | 107,918 | * |
| Manfred K. Kruger (6) | 590,625 | 3.57 |
| George Lombardi (6) | 215,000 | 1.33 |
| Guy L. Mayer (6) | 75,000 | * |
| Adrian J. R. Smith (6) | 10,000 | * |
| Carlton E. Turner (6) | 42,500 | * |
| All directors and officers as a group (11 persons) | 1,321,343 | 7.71 |

* Less than 1%

(1) In accordance with Rule 13d-3 promulgated pursuant to the Exchange Act, a person is deemed to be the beneficial owner of the security for purposes of the rule if he or she has or shares voting power or dispositive power with

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

respect to such security or has the right to acquire such ownership within sixty days. As used herein, "voting power" is the power to vote or direct the voting of shares and "dispositive power" is the power to dispose or direct the disposition of shares, irrespective of any economic interest therein.

- (2) Except as otherwise indicated by footnote, the persons named in the table have sole voting and investment power with respect to all of the common stock beneficially owned by them.
- (3) In calculating the percentage ownership for a given individual or group, the number of shares of common stock outstanding includes unissued shares subject to options, warrants, rights or conversion privileges exercisable within sixty days after November 30, 2005 held by such individual or group.
- (4) Includes 42,500 shares of common stock issuable upon exercise of options exercisable within sixty (60) days. Mr. Cleveland is the President and majority shareholder of Renaissance Capital Group, Inc. His business address is 8080 N. Central Expressway, Suite 210-LB 59, Dallas, TX 75206.
- (5) Includes 27,500 shares of common stock issuable upon exercise of options and warrants exercisable within sixty (60) days.
- (6) All of the shares of common stock beneficially owned by Messrs. Henseler, Koschatzky, Kruger, Lombardi, Mayer, Smith and Turner are derivative securities issuable upon exercise of options exercisable within sixty (60) days.
- (7) Includes 10,000 of common stock issuable upon exercise of options and warrants exercisable within sixty (60) days.
- (8) Includes 82,500 of common stock issuable upon exercise of options and warrants exercisable within sixty (60) days.

23

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

The Company has an exclusive license and distribution agreement with Zimmer Spine, a wholly owned subsidiary of Zimmer Holdings, Inc., whereby Zimmer Spine has been granted the right to act as the Company's exclusive distributor of bone tissue for spinal applications in the United States. For the year ended September 30, 2005, Spine revenues were \$3.3 million.

The Company has also engaged Zimmer Dental, a wholly owned subsidiary of Zimmer Holdings, Inc., to act as an exclusive distributor for the Company's bone tissue for dental applications in the United States and certain international markets. For the year ended September 30, 2005, Zimmer Dental was paid commissions aggregating approximately \$6.1 million on revenues of \$13.8 million.

Zimmer CEP (formerly Centerpulse) USA Holding Co. is the owner of approximately 33.3% of the Company's outstanding shares of Common Stock.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

The following table represents the aggregate fees billed for professional audit services rendered to the Company by Deloitte & Touche, LLP for the audit of the Company's annual financial statements for the years ended September 30, 2005 and 2004, and all fees billed for other services by Deloitte & Touche LLP during those periods:

| Year Ended September 30, | 2005 | 2004 |
|--------------------------|------------|------------|
| Audit fees (1) | \$ 143,000 | \$ 105,500 |
| Audit-related fees (2) | 55,000 | 27,900 |
| Tax fees (3) | 4,000 | 3,100 |
| All other fees (4) | - | - |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | | |
|------------------------------------|----|---------|----|---------|
| Total Accounting Fees and Services | \$ | 202,000 | \$ | 136,500 |
|------------------------------------|----|---------|----|---------|

- (1) AUDIT FEES. These are fees for professional services for the audit of the Company's annual financial statements, and for the review of the financial statements included in the Company's filings on Form 10Q and for services that are normally provided in connection with statutory and regulatory filings or engagements.
- (2) AUDIT-RELATED FEES. These are fees for the assurance and related services reasonably related to the performance of the audit or the review of the Company's financial statements.
- (3) TAX FEES. These are fees for professional services with respect to tax compliance, tax advice, and tax planning.
- (4) ALL OTHER FEES. These are fees for permissible work that does not fall within any of the other fee categories, i.e., Audit Fees, Audit-Related Fees, or Tax Fees.

PRE-APPROVAL POLICY FOR AUDIT AND NON-AUDIT SERVICES

The Company's Audit Committee has responsibility for the approval of all audit and non-audit services before the Company engages an accountant. All of the services rendered to the Company by Deloitte & Touche for the fiscal years ended September 30, 2005 and 2004 were pre-approved by the Audit Committee before the engagement of the auditors for such services.

The Company and the Audit Committee are working with the Company's legal counsel to establish formal pre-approval policies and procedures for all future engagements of the Company's accountants. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission relating to the independence of auditors, the Company's new pre-approval policies and procedures will be detailed as to particular services, will require that the Audit Committee be informed of each service, and will prohibit the delegation of any pre-approval responsibilities to the Company's management.

The Company's pre-approval policy will expressly provide for the annual pre-approval of all audits, audit-related and all non-audit services proposed to be rendered by the independent auditor for the fiscal year, as specifically described in the auditor's engagement letter, such annual pre-approval to be performed by the Audit Committee. The new policy will also provide that all additional engagements of the auditor that were not approved in the annual pre-approval process, and all engagements that are anticipated to exceed previously approved thresholds, shall be presented by the President or Chief Financial Officer of the Company to the Audit Committee for pre-approval, on a case-by-case basis, before management engages the auditors for any such purposes. The Audit Committee may be authorized to delegate, to one or more of its members, the authority to pre-approve certain permitted services, provided that the estimated fee for any such service does not exceed a specified dollar amount.

All pre-approvals shall be contingent on a finding, by the Audit Committee, or delegates thereof, as the case may be, that the provision of the proposed services by the Company's auditor is compatible with the maintenance of the auditor's independence in the conduct of its auditing functions. In no event shall any non-audit related service be approved that would result in the independent auditor no longer being considered independent under the applicable rules and regulations of the Securities and Exchange Commission.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

- (A) INDEX TO EXHIBITS
- 3.2 Articles of Incorporation of Registrant.**
- 3.3 Articles of Amendment to Articles of Incorporation Establishing Series A Preferred Stock.*
- 3.4 Articles of Amendment to Articles of Incorporation Establishing Series B Preferred Stock.*
- 3.5 Articles of Amendment to Articles of Incorporation Establishing Series C Preferred Stock.*
- 3.6 Articles of Amendment to Articles of Incorporation Increasing the Number of Authorized Shares.*
- 3.7 Articles of Amendment to Articles of Incorporation Amending the Terms of the Series C Preferred Stock.*
- 3.8 Articles of Amendment to Articles of Incorporation Effecting Reverse Stock Split*
- 10.7 Employment Agreement between the Registrant and Manfred Kruger dated June 9, 1997. *
- 10.9 Employment Agreement between the Registrant and Mr. Guy Mayer dated December 6, 2004.*****
- 14 Code of Ethics****
- 21 Subsidiaries of Registrant*
- 31.1 Certification of Chief Executive Officer, pursuant to Rule 13a-14. ***
- 31.2 Certification of Chief Financial Officer, pursuant to Rule 13a-14. ***
- 32. Certification of Chief Executive Officer and the Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***

* Document incorporated by reference from previous Form 10-KSB filings.

** Document incorporated by reference from Exhibit 2 of Registration Statement, on Form 20-F, of American Biodynamics, Inc., effective October 2, 1987.

*** Filed herewith.

**** Filed with the Company's Form 10-K for the year ended September 30, 2004.

***** Filed with the Company's Form 10-K for the year ended September 30, 2005.

(B) FINANCIAL STATEMENT SCHEDULES

Report of Independent Registered Public Accounting Firm on Schedule II***

Schedule II - Valuation and Qualifying Accounts for the years ended September 30, 2005, 2004 and 2003.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Schedules other than that listed have been omitted because they are not required or are not applicable or because the information required to be set forth therein either is not material or is included in the financial statements or notes thereto.

25

SIGNATURES

In accordance with the Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Amendment No. 1 to its Annual Report on Form 10-K/A to be signed on behalf by the undersigned, thereunto duly authorized.

Date: July 6, 2006

TUTOGEN MEDICAL, INC.

/s/ Guy L. Mayer

Guy L. Mayer
Chief Executive Officer

/s/ L. Robert Johnston Jr.

L. Robert Johnston Jr.
Chief Financial Officer, Treasurer and
Secretary

26

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of
Tutogen Medical, Inc. and Subsidiaries
West Paterson, New Jersey

We have audited the accompanying consolidated balance sheets of Tutogen Medical, Inc. and subsidiaries (the "Company") as of September 30, 2005 and 2004, and the related consolidated statements of (loss) income and comprehensive (loss) income, shareholders' equity, and cash flows for each of the three years in the period ended September 30, 2005. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of September 30, 2005 and 2004, and the results of their operations and their cash flows for each of the three years in the period ended September 30, 2005, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 16, the accompanying consolidated financial statements have been restated.

/s/ Deloitte & Touche LLP
 Certified Public Accountants
 Orlando, Florida

December 8, 2005

(July 5, 2006, as to the effects of the restatements discussed in Note 16)

F-1

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
 CONSOLIDATED BALANCE SHEETS
 SEPTEMBER 30, 2005 AND 2004
 (In Thousands)

| | 2005 ---- | 2004 ---- |
|---|----------------------------|--------------------|
| ASSETS | (AS RESTATED, SEE NOTE 16) | |
| CURRENT ASSETS: | | |
| Cash and cash equivalents | \$ 3,562 | \$ 5,063 |
| Accounts receivable, net of allowance for doubtful accounts of \$462 in 2005 and \$192 in 2004 | 3,473 | 4,922 |
| Inventories - net | 9,554 | 14,261 |
| Deferred tax asset | 1,149 | 673 |
| Other current assets | 623 | 1,409 |
| | ----- | ----- |
| Total current assets | 18,361 | 26,328 |
| PROPERTY, PLANT AND EQUIPMENT - Net | 6,612 | 6,138 |
| DEFERRED TAX ASSET | 1,232 | 1,070 |
| | ----- | ----- |
| TOTAL ASSETS | \$ 26,205 ===== | \$ 33,536 ===== |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:

| | | |
|---|----------|----------|
| Accounts payable and other accrued expenses | \$ 6,342 | \$ 6,521 |
| Accrued commissions | 1,765 | 1,521 |
| Short term borrowing | 1,048 | - |
| Current portion of deferred distribution fees | 589 | 642 |
| Current portion of long-term debt | 184 | 173 |

| | | |
|---------------------------|-------|-------|
| Total current liabilities | 9,928 | 8,857 |
|---------------------------|-------|-------|

NONCURRENT LIABILITIES:

| | | |
|----------------------------|-------|-------|
| Deferred distribution fees | 1,925 | 2,580 |
| Long-term debt | 630 | 827 |

| | | |
|-------------------|--------|--------|
| TOTAL LIABILITIES | 12,483 | 12,264 |
|-------------------|--------|--------|

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:

| | | |
|--|----------|----------|
| Common stock, \$0.01 par value, 30,000,000 authorized; 15,932,960 and 15,915,960 shares issued and outstanding, respectively | 159 | 158 |
| Additional Paid-in Capital | 36,381 | 36,345 |
| Accumulated other comprehensive income | 1,678 | 2,248 |
| Accumulated Deficit | (24,496) | (17,479) |

| | | |
|----------------------------|--------|--------|
| Total shareholders' equity | 13,722 | 21,272 |
|----------------------------|--------|--------|

| | | |
|--|-----------|-----------|
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | \$ 26,205 | \$ 33,536 |
|--|-----------|-----------|

See notes to consolidated financial statements.

F-2

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF (LOSS) INCOME AND COMPREHENSIVE (LOSS) INCOME

YEARS ENDED SEPTEMBER 30, 2005, 2004 AND 2003

(In Thousands, Except for Share and Per Share Data)

| | 2005 | 2004 | 2003 |
|----------------------------|----------------------------|-----------|-----------|
| | (AS RESTATED, SEE NOTE 16) | | |
| REVENUE | \$ 31,860 | \$ 29,330 | \$ 30,000 |
| COST OF REVENUE | 20,510 | 12,206 | 10,000 |
| Gross profit | 11,350 | 17,124 | 20,000 |
| OPERATING EXPENSES: | | | |
| General and administrative | 5,409 | 4,203 | 4,000 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | |
|--|------------|------------|--------|
| Distribution and marketing | 11,509 | 8,737 | 8 |
| Research and development | 1,659 | 1,432 | |
| Litigation contingency | - | (406) | |
| | ----- | ----- | ----- |
| Total operating expenses | 18,577 | 13,966 | 14 |
| | ----- | ----- | ----- |
| OPERATING (LOSS) INCOME | (7,227) | 3,158 | 5 |
| OTHER EXPENSE | (96) | (601) | |
| INTEREST EXPENSE | (130) | (118) | |
| | ----- | ----- | ----- |
| (LOSS) INCOME BEFORE (BENEFIT) PROVISION FOR INCOME TAXES | (7,453) | 2,439 | 4 |
| (BENEFIT) PROVISION FOR INCOME TAXES | (436) | 1,306 | 1 |
| | ----- | ----- | ----- |
| NET (LOSS) INCOME | (7,017) | 1,133 | 3 |
| COMPREHENSIVE (LOSS) INCOME: Foreign currency translation (loss) gain | (570) | 2,167 | 1 |
| | ----- | ----- | ----- |
| COMPREHENSIVE (LOSS) INCOME | \$ (7,587) | \$ 3,300 | \$ 4 |
| | ===== | ===== | ===== |
| AVERAGE SHARES OUTSTANDING FOR BASIC (LOSS) EARNINGS PER SHARE | 15,919,286 | 15,734,470 | 15,495 |
| | ===== | ===== | ===== |
| BASIC (LOSS) EARNINGS PER SHARE: | \$ (0.44) | \$ 0.07 | \$ |
| | ===== | ===== | ===== |
| AVERAGE SHARES OUTSTANDING FOR DILUTED (LOSS) EARNINGS PER SHARE | 15,919,286 | 16,469,443 | 16,095 |
| | ===== | ===== | ===== |
| DILUTED (LOSS) EARNINGS PER SHARE: | \$ (0.44) | \$ 0.07 | \$ |
| | ===== | ===== | ===== |

See notes to consolidated financial statements.

F-3

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 2005, 2004 AND 2003
(IN THOUSANDS)

2005

2004

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | (AS RESTATED, SE | |
|---|------------------|---------|
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Net (loss) income | \$ (7,017) | \$ 1,13 |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | | |
| Depreciation and amortization | 984 | 76 |
| Deferred distribution fees revenue | (640) | (64 |
| Reserve for bad debts | 175 | (24 |
| Reserve for obsolescence | 889 | (95 |
| Deferred income taxes | (505) | 86 |
| Changes in assets and liabilities: | | |
| Accounts receivable | 1,239 | 96 |
| Inventories | 3,771 | (1,45 |
| Other current assets | 798 | (24 |
| Accounts payable and other accrued expenses | (497) | (89 |
| Accrued commissions | 244 | 1,07 |
| | ----- | ----- |
| Net cash (used in) provided by operating activities | (559) | 38 |
| | ----- | ----- |
| CASH FLOWS USED IN INVESTING ACTIVITIES: | | |
| Purchase of property and equipment | (1,682) | (1,75 |
| | ----- | ----- |
| Net cash used in investing activities | (1,682) | (1,75 |
| | ----- | ----- |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Issuance of common stock | 36 | 36 |
| Proceeds from revolving credit arrangements | 1,508 | |
| Repayment of revolving credit arrangements | (400) | |
| Proceeds from long-term borrowings | - | 22 |
| Repayment of long-term debt | (164) | (9 |
| | ----- | ----- |
| Net cash provided by financing activities | 980 | 49 |
| | ----- | ----- |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH | (240) | 89 |
| | ----- | ----- |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (1,501) | 1 |
| CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR | 5,063 | 5,04 |
| | ----- | ----- |
| CASH AND CASH EQUIVALENTS, END OF YEAR | \$ 3,562 | \$ 5,06 |
| | ===== | ===== |
| SUPPLEMENTAL CASH FLOW DISCLOSURE: | | |
| Interest paid | \$ 127 | \$ 11 |
| | ===== | ===== |
| Income taxes paid | \$ 149 | \$ 25 |
| | ===== | ===== |

See notes to consolidated financial statements.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
YEARS ENDED SEPTEMBER 30, 2005, 2004 AND 2003
(In Thousands, Except for Share Data)

| | COMMON SHARES (\$.01 PAR) | ADDITIONAL PAID-IN CAPITAL | ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (1) | ACCUMULATED DEFICIT |
|---|----------------------------------|----------------------------------|--|------------------------|
| BALANCE, SEPTEMBER 30, 2002, as previously reported | \$ 152 | \$ 35,135 | \$ (925) | \$ (20,430) |
| Prior period adjustment (see Note 16) | - | - | - | (1,880) |
| BALANCE, SEPTEMBER 30, 2002 (as restated, see Note 16) | 152 | 35,135 | (925) | (22,310) |
| Stock issued on exercise of options | 5 | 845 | - | - |
| Net income (as restated, see Note 16) | - | - | - | 3,700 |
| Foreign currency translation adjustment | - | - | 1,006 | - |
| BALANCE, SEPTEMBER 30, 2003 (as restated, see Note 16) | 157 | 35,980 | 81 | (18,610) |
| Stock issued on exercise of options | 2 | 365 | - | - |
| Net income (as restated, see Note 16) | - | - | - | 1,130 |
| Foreign currency translation adjustment | - | - | 2,167 | - |
| BALANCE, SEPTEMBER 30, 2004 (as restated, see Note 16) | 159 | 36,345 | 2,248 | (17,470) |
| Stock issued on exercise of options | - | 36 | - | - |
| Net loss (as restated, see Note 16) | - | - | - | (7,010) |
| Foreign currency translation adjustment (as restated, see Note 16) | - | - | (570) | - |
| BALANCE, SEPTEMBER 30, 2005 (as restated, see Note 16) | \$ 159 | \$ 36,381 | \$ 1,678 | \$ (24,490) |

(1) Represents foreign currency translation adjustments.

See accompanying Notes to Consolidated Financial Statements.

F-5

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED SEPTEMBER 30, 2005, 2004 AND 2003
(IN THOUSANDS, EXCEPT FOR SHARE DATA)

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

1. OPERATIONS AND ORGANIZATION

Tutogen Medical, Inc. with its consolidated subsidiaries (the "Company") processes, manufactures and distributes worldwide, specialty surgical products and performs tissue processing services for neuro, orthopedic, reconstructive and general surgical applications. The Company's core business is processing human donor tissue, utilizing its patented Tutoplast(R) process, for distribution to hospitals and surgeons. The Company processes at its two manufacturing facilities in Germany and the United States and distributes its products and services to over 30 countries worldwide.

2. SIGNIFICANT ACCOUNTING POLICIES

Significant accounting policies of the Company are presented below.

PRINCIPLES OF CONSOLIDATION - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation.

FOREIGN CURRENCY TRANSLATION - The functional currency of the Company's German subsidiary is the Euro. Assets and liabilities of foreign subsidiaries are translated at the period end exchange rate while revenues and expenses are translated at the average exchange rate for the year. The resulting translation adjustments, representing unrealized, noncash losses are made directly to comprehensive income. Gains and losses resulting from transactions of the Company and its subsidiaries, which are made in currencies different from their own, are included in income as they occur and are included in Other Expense (Income) in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. The Company recognized translation losses of \$173, \$700 and \$350 in 2005, 2004 and in 2003, respectively.

FAIR VALUE OF FINANCIAL INSTRUMENTS - The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined by using available market information and appropriate valuation methodologies. The carrying value of long-term debt approximates fair value.

CASH AND CASH EQUIVALENTS - The Company considers all highly liquid investments purchased with a remaining maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments.

INVENTORIES - Inventories are valued at the lower of cost (weighted average basis) or market. Work in process and finished goods includes costs attributable to direct labor and overhead. Reserves for slow moving and obsolete inventories are provided based on historical experience and current product demand. The adequacy of these reserves is evaluated quarterly.

PROPERTY, PLANT AND EQUIPMENT - Property, plant and equipment are stated at cost. Depreciation is computed by using the straight-line method over the following estimated useful lives of the assets:

| | |
|--|------------|
| Building and improvements | 40 years |
| Machinery, equipment, furniture and fixtures | 3-10 years |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

IMPAIRMENT OF LONG-LIVED ASSETS -Periodically, the Company evaluates the recoverability of the net carrying amount of its property, plant and equipment and its intangible assets by comparing the carrying amounts to the estimated future undiscounted cash flows generated by those assets. If the sum of the estimated future undiscounted cash flows were less than the carrying amount of the asset, a loss would be recognized for the difference between the fair value and the carrying amount.

In the event that facts and circumstances indicate that the cost of long-lived assets, primarily property, plant and equipment and certain identifiable intangible assets may be impaired, the Company performs a recoverability evaluation. If an evaluation is required, the undiscounted estimated future cash flows associated with the assets are compared to the assets' carrying amount to determine whether a write-down to fair value is required.

F-6

Impairment losses are measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risks associated with the recovery of the assets. Assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.

REVENUE AND COST OF REVENUE - Revenue includes amounts from surgical products and related services and distribution fees. Cost of revenue includes depreciation of \$686, \$311 and \$404 for the years ended September 30, 2005, 2004 and 2003, respectively. Revenue from surgical products and related services is recognized upon the shipment of the processed tissues and when services are performed. The Company's terms of sale are FOB shipping point. Revenue from distribution fees includes nonrefundable payments received as a result of exclusive distribution agreements between the Company and independent distributors. Distribution fees under these arrangements are recognized as revenue on a straight-line basis over the contract period.

RESEARCH AND DEVELOPMENT COSTS - Research and development costs are charged to operations as incurred.

EARNINGS PER SHARE - Basic earnings per share are computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted earnings per share are computed by dividing net income (loss) by the sum of the weighted-average number of common shares outstanding plus the potentially dilutive effect of shares issuable through deferred stock units and the exercise of stock options and warrants.

USE OF ESTIMATES - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

TOTAL COMPREHENSIVE INCOME (LOSS) - The Company follows Statement of Financial Accounting Standard ("SFAS") No. 130, REPORTING COMPREHENSIVE INCOME (LOSS). Comprehensive income is defined as the total change in

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

shareholders' equity during the period other than from transactions with shareholders, and for the Company, includes net income and cumulative translation adjustments.

INCOME TAXES - Deferred taxes are provided for the expected future income tax consequences of events that have been recognized in the Company's financial statements. Deferred tax assets and liabilities are determined based on the temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to amounts, which are more likely than not to be realized.

STOCK-BASED COMPENSATION - SFAS No. 123, ACCOUNTING FOR STOCK-BASED COMPENSATION ("SFAS 123"), requires expanded disclosure of stock-based compensation arrangements with employees and encourages (but does not require) compensation cost to be measured based on the fair value of the equity instrument awarded. Corporations are permitted, however, to continue to apply Accounting Principles Board ("APB") Opinion No. 25, which recognizes compensation cost based on the intrinsic value of the equity instrument awarded. The Company has continued to apply APB Opinion No. 25 to its stock-based compensation awards to employees and has disclosed the required pro forma effect on net income.

The Financial Accounting Standards Board ("FASB") issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure, which amends SFAS No. 123, Accounting for Stock-Based Compensation. SFAS 148 provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. (Under the fair value based method, compensation cost for stock options is measured when options are issued). In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require more prominent and more frequent disclosures in financial statements of the effects of stock-based compensation. The Company adopted SFAS No. 148 beginning in the second fiscal quarter of fiscal 2003 and such disclosures are included as herein.

F-7

The following table reconciles net income (loss) and basic and diluted earnings (loss) per share (EPS), as reported, to pro-forma net income (loss) and basic and diluted EPS, as if the Company had expensed the fair value of stock options.

| | 2005 ---- | 2004 ---- |
|--|---------------------|-----------------|
| Net (loss) income: | \$ (7,017) | \$ 1,133 |
| Deduct: Total stock-based employee compensation expense determined under fair value based method, net of related tax effects | 102 | 159 |
| Pro forma net (loss) income | \$ (7,119) ===== | \$ 974 ===== |
| Basic EPS: | | |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | |
|---------------------------------------|-----------|---------|
| As reported | \$ (0.44) | \$ 0.07 |
| Pro forma using the fair value method | \$ (0.45) | \$ 0.06 |
| Diluted EPS: | | |
| As reported | \$ (0.44) | \$ 0.07 |
| Pro forma using the fair value method | \$ (0.45) | \$ 0.06 |

NEW ACCOUNTING PRONOUNCEMENTS - In December 2004, the Financial Accounting Standards Board ("FASB") issued Statement 123R ("SFAS 123R"), SHARE-BASED PAYMENT, that will require compensation costs related to share-based payment transactions to be recognized in the financial statements. On April 14, 2005, the compliance date for SFAS 123R was extended. The Company will be required to comply with SFAS 123R for the three months ended December 31, 2005. The Company is currently assessing the impact of adopting SFAS 123R on the results of operations or financial position of the Company.

In March 2005, the Securities and Exchange Commission (the "SEC") issued Staff Accounting Bulletin ("SAB") No. 107, SHARE-BASED PAYMENT ("SAB No. 107"), which provides interpretive guidance related to the interaction between SFAS No. 123R and certain SEC rules and regulations, as well as provides the SEC staff's views regarding the valuation of share-based payment arrangements. The Company is currently assessing the impact of adopting SAB No. 107 on the results of operations or financial position of the Company.

In November 2004, the FASB issued SFAS No. 151, INVENTORY COSTS, AN AMENDMENT OF ARB NO. 43. SFAS No. 151 requires idle facility expenses, freight, handling costs, and wasted material (spoilage) costs to be excluded from the cost of inventory and expensed when incurred. It also requires that allocation of fixed overheads to the costs of conversion be based on the normal capacity of the production facilities. This statement is effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The adoption of SFAS No. 151 is not expected to have a material impact on the results of operations or financial position of the Company.

EMPLOYEE SAVINGS PLAN - The Company maintains the Tutogen Medical, Inc. 401(k) Plan (the "Plan") for which all of the United States Employees are eligible. The Plan requires the attainment of the age of 21 and a minimum of six months of employment to become a participant. Participants may contribute up to the maximum dollar limit set by the Internal Revenue Service. The expenses incurred for the Plan were \$57, \$73 and \$55 in 2005, 2004 and 2003, respectively.

RECLASSIFICATION - Certain reclassifications have been made to the prior financial statements to conform to the current presentation.

3. CONCENTRATION OF CREDIT RISK

The exposure to risk related to foreign currency exchange rate changes is limited primarily to intercompany transactions. The Company currently does not utilize forward exchange contracts or any other type of hedging instruments.

The Company's principal concentration of credit risk consists of trade receivables. Distribution of products and revenues is provided through a broad base of independent distributors. Two customers accounted for 10% and 8%, respectively, of consolidated revenue in

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

F-8

2005, while the same two customers accounted for 13% and 9%, respectively of consolidated revenue in 2004 and 17% and 13%, respectively in 2003. The 10% and 8% customers had accounts receivable balances at September 30, 2005 of \$347 and \$288, respectively. There are no other customers accounting for greater than 10% of consolidated revenue in 2005, 2004 and 2003. The Company does not believe that this concentration of sales and credit risks represents a material risk of loss with respect to the results of operations or financial position.

4. INVENTORIES

Major classes of inventory at September 30, 2005 and 2004 were as follows:

| | 2005 | 2004 |
|--------------------------------|----------|-----------|
| Raw materials | \$ 1,753 | \$ 2,171 |
| Work in process | 4,219 | 6,035 |
| Finished goods | 6,860 | 8,505 |
| | ----- | ----- |
| | 12,832 | 16,711 |
| Less reserves for obsolescence | 3,278 | 2,450 |
| | ----- | ----- |
| | \$ 9,554 | \$ 14,261 |
| | ===== | ===== |

5. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at September 30, 2005 and 2004 consisted of the following:

| | 2005 | 2004 |
|--|----------|----------|
| Land | \$ 495 | \$ 512 |
| Buildings and improvements | 3,835 | 3,876 |
| Machinery and equipment | 2,329 | 2,201 |
| Office furniture and equipment | 2,787 | 2,570 |
| Construction-in-progress | 883 | 472 |
| | ----- | ----- |
| | 10,329 | 9,631 |
| Less accumulated depreciation and amortization | (3,717) | (3,493) |
| | ----- | ----- |
| | \$ 6,612 | \$ 6,138 |
| | ===== | ===== |

The depreciation expense for the years ended September 30, 2005, 2004 and 2003 was \$984, \$760 and \$611, respectively.

6. REVOLVING CREDIT ARRANGEMENTS

Under the terms of revolving credit facilities with three German banks, all of which have no expiration, the Company may borrow up to Euros

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

1,500 million or approximately \$1,800 for working capital needs. These renewable credit lines allow the Company to borrow at interest rates ranging from 9.15% to 10.5%. At September 30, 2005, and 2004 the Company had no borrowings under the revolving credit agreements.

The Company has a revolving credit facility in the U.S. for up to \$1,000, expiring on January 1, 2006. At September 2005 and 2004, the Company had no borrowings under this credit facility. The U.S. accounts receivable and inventory assets secure the borrowing under the revolving credit facility.

The Company has an interim loan of up to Euros 1,500 million or approximately \$1,800, at an annual interest rate of 5%, to finance its facility expansion project in Germany. The interim loan will convert to a long-term arrangement at the completion of approximately \$1,800 of funding, estimated to be no later than March 31, 2006. At September 30, 2005, the Company had short-term borrowings of \$1,048.

F-9

7. LONG-TERM DEBT

Long-term debt at September 30, 2005 and 2004 consisted of the following:

| | 2005 | 2004 |
|--|--------|--------|
| Senior debt, 5.75% interest until March 30, 2008 when terms are renegotiable, due 2008 | \$ 651 | \$ 776 |
| Equipment lease debt, 6.50% interest until September 1, 2007 | 163 | 224 |
| | ----- | ----- |
| | 814 | 1,000 |
| Less current portion | (184) | (173) |
| | ----- | ----- |
| | \$ 630 | \$ 827 |
| | ===== | ===== |

Aggregate maturities of long-term debt are \$184 in 2006; \$197 in 2007; \$433 in 2008.

The Senior debt and one of the revolving credit facilities are with a German bank and are secured by a mortgage on the Company's German facility. The Senior debt is repayable in monthly installments through 2008. The debt has been incurred by the Company's German subsidiary but is guaranteed by the parent company. There are no financial covenants under this debt.

The Equipment lease debt is secured by a specific piece of equipment, a walk-in freezer, located at the Company's Florida manufacturing facility. The lease is payable in twelve quarterly installments of \$21. There are no financial covenants under this lease.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

8. SHAREHOLDERS' EQUITY

STOCK - The authorized stock of the Company consists of 30,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock.

PREFERRED SHARE PURCHASE RIGHT - On July 17, 2002, the Board of Directors of the Company declared a dividend distribution of one Preferred Share Purchase Right for each outstanding share of its common stock of record on July 31, 2002. The rights, which expire on July 30, 2012, are designed to assure that all of the Company's shareholders receive fair and equal treatment in the event of any proposed takeover of the Company. Each right will entitle its holder to purchase, at the right's then current exercise price, a number of the Company's common shares having a market value of twice such price.

STOCK OPTIONS - The Company maintains a 1996 Stock Option Plan (the "Plan") (4,000,000 shares authorized) under which incentive and nonqualified options have been granted to employees, directors and certain key affiliates. Under the Plan, options may be granted at not less than the fair market value on the date of grant. Options may be subject to a vesting schedule and expire four, five or ten years from grant.

F-10

Changes in outstanding options for the Plan were as follows:

| | NUMBER OF COMMON SHARES | WEIGHTED AVERAGE EXERCISE PRICE |
|--------------------------------|-------------------------------|--|
| Outstanding October 1, 2002 | 2,217,668 | \$ 2.44 |
| Granted | 452,500 | 2.91 |
| Canceled | (204,800) | 3.33 |
| Exercised | (209,000) | (1) 1.81 |
| | ----- | |
| Outstanding September 30, 2003 | 2,256,368 | 2.52 |
| Granted | 225,000 | 3.98 |
| Canceled | (93,750) | 4.45 |
| Exercised | (248,850) | 1.47 |
| | ----- | |
| Outstanding September 30, 2004 | 2,138,768 | 2.72 |
| Granted | 622,000 | 2.99 |
| Canceled | (262,400) | 4.03 |
| Exercised | (17,000) | 2.17 |
| | ----- | ----- |
| Outstanding September 30, 2005 | 2,481,368 | \$ 2.64 |
| | ===== | ===== |

(1) Does not include 300,000 stock options exercised into common shares that represented a special stock option grant in 1997, to a former executive officer outside of the 1996 stock option plan. The shares vested 120,000 upon issue, and 180,000 one year

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

after issue.

As of September 30, 2005, 348,303 stock options were available for grant.

The following table provides information about stock options outstanding at September 30, 2005:

| RANGE OF EXERCISE PRICE ----- | OPTIONS OUTSTANDING | | | OPTIONS EXERCISABLE | |
|-------------------------------------|--|---|--|--|---------------------------|
| | NUMBER OUTSTANDING AS OF 9/30/05 | WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (IN YEARS) | WEIGHTED AVERAGE EXERCISE PRICE | NUMBER EXERCISABLE AS OF 9/30/05 | WEIG AVE EXER PR |
| \$0.94 to \$1.25 | 299,600 | 3.9 | \$ 0.95 | 299,600 | \$ 0 |
| \$1.56 to \$2.22 | 652,568 | 2.7 | 1.77 | 602,568 | 1 |
| \$2.40 to \$3.62 | 1,051,500 | 6.5 | 2.83 | 637,375 | 2 |
| \$3.75 to \$11.00 | 477,700 | 6.2 | 4.46 | 306,950 | 4 |
| | ----- | ---- | ----- | ----- | ---- |
| \$0.94 to \$11.00 | 2,481,368 | 5.1 | \$ 2.64 | 1,846,493 | \$ 2 |
| | ===== | ==== | ===== | ===== | ==== |

The fair value of each option is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 47%, a risk-free interest rate range of 2.26% to 3.12% and an expected life of four years. A dividend yield of zero has been assumed. The weighted average fair value of options granted during the years ended September 30, 2005, 2004 and 2003 was \$2.99, \$3.98 and \$2.91 respectively.

9. SEGMENT DATA

The Company operates principally in one industry providing specialty surgical products and tissue processing services. These operations include two geographically determined segments: the United States and Europe ("International"). The accounting policies of these segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on the operating income. The Company accounts for intersegment sales and transfers at contractually agreed-upon prices.

The Company's reportable segments are strategic business units that offer products and services to different geographic markets. They are managed separately because of the differences in these markets as well as their physical location.

F-11

A summary of the operations and assets by segment as of and for the years ended September 30, 2005, 2004 and 2003 are as follows:

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| 2005 | INTERNATIONAL | UNITED STATES | CONSOLIDATED |
|-------------------------------|---------------|---------------|--------------|
| Gross revenue | \$ 17,344 | \$ 21,752 | \$ 39,096 |
| Less - intercompany | (7,236) | - | (7,236) |
| | ----- | ----- | ----- |
| Total revenue - third party | \$ 10,108 | \$ 21,752 | \$ 31,860 |
| | ===== | ===== | ===== |
| Depreciation and amortization | \$ 615 | \$ 369 | \$ 984 |
| | ===== | ===== | ===== |
| Operating Loss | \$ (974) | \$ (6,253) | \$ (7,227) |
| | ===== | ===== | ===== |
| Interest expense | \$ 61 | \$ 69 | \$ 130 |
| | ===== | ===== | ===== |
| Net Loss | \$ (1,037) | \$ (5,980) | \$ (7,017) |
| | ===== | ===== | ===== |
| Capital expenditures | \$ 1,468 | \$ 213 | \$ 1,681 |
| | ===== | ===== | ===== |
| Identifiable assets | \$ 16,200 | \$ 10,005 | \$ 26,205 |
| | ===== | ===== | ===== |
| | | | |
| 2004 | INTERNATIONAL | UNITED STATES | CONSOLIDATED |
| Gross revenue | \$ 22,830 | \$ 17,126 | \$ 39,956 |
| Less - intercompany | (10,626) | - | (10,626) |
| | ----- | ----- | ----- |
| Total revenue - third party | \$ 12,204 | \$ 17,126 | \$ 29,330 |
| | ===== | ===== | ===== |
| Depreciation and amortization | \$ 506 | \$ 254 | \$ 760 |
| | ===== | ===== | ===== |
| Operating income (loss) | \$ 4,179 | \$ (1,021) | \$ 3,158 |
| | ===== | ===== | ===== |
| Interest expense | \$ 79 | \$ 39 | \$ 118 |
| | ===== | ===== | ===== |
| Net income (loss) | \$ 2,289 | \$ (1,156) | \$ 1,133 |
| | ===== | ===== | ===== |
| Capital expenditures | \$ 1,244 | \$ 515 | \$ 1,759 |
| | ===== | ===== | ===== |
| Identifiable assets | \$ 18,166 | \$ 15,370 | \$ 33,536 |
| | ===== | ===== | ===== |

F-12

| 2003 | INTERNATIONAL | UNITED STATES | CONSOLIDATED |
|------|---------------|---------------|--------------|
|------|---------------|---------------|--------------|

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | |
|-------------------------------|-----------|-----------|-----------|
| Gross revenue | \$ 18,079 | \$ 21,168 | \$ 39,247 |
| Less - intercompany | (8,987) | - | (8,987) |
| | ----- | ----- | ----- |
| Total revenue - third party | \$ 9,092 | \$ 21,168 | \$ 30,260 |
| | ===== | ===== | ===== |
| Depreciation and amortization | \$ 376 | \$ 235 | \$ 611 |
| | ===== | ===== | ===== |
| Operating income (loss) | \$ 5,450 | \$ (185) | \$ 5,265 |
| | ===== | ===== | ===== |
| Interest expense | \$ 47 | \$ 6 | \$ 53 |
| | ===== | ===== | ===== |
| Net income | \$ 3,589 | \$ 118 | \$ 3,707 |
| | ===== | ===== | ===== |
| Capital expenditures | \$ 470 | \$ 220 | \$ 690 |
| | ===== | ===== | ===== |
| Identifiable assets | \$ 16,105 | \$ 13,846 | \$ 29,951 |
| | ===== | ===== | ===== |

Total International long-lived assets of \$5,912, \$5,282 and \$4,247 for the years ended September 30, 2005, 2004 and 2003, respectively are located in Germany.

10. INCOME TAXES

The (benefit of) provision for income taxes for the years ended September 30, 2005, 2004 and 2003 are summarized as follows:

| | 2005 | 2004 | 2003 |
|---|----------|----------|----------|
| Current: | | | |
| Federal | \$ - | \$ - | \$ (15) |
| State | - | - | - |
| Foreign | - | 1,153 | - |
| | ----- | ----- | ----- |
| | - | 1,153 | (15) |
| | ----- | ----- | ----- |
| Deferred: | | | |
| Federal | (2,260) | (737) | 335 |
| State | (194) | (162) | 75 |
| Foreign | (571) | 153 | 1,152 |
| | ----- | ----- | ----- |
| | (3,025) | (746) | 1,562 |
| | ----- | ----- | ----- |
| Valuation allowance | 2,589 | 899 | (410) |
| | ----- | ----- | ----- |
| (Benefit of) provision for income taxes | \$ (436) | \$ 1,306 | \$ 1,137 |
| | ===== | ===== | ===== |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

The differences between the U.S. statutory rates and those in the consolidated financial statements of operations and comprehensive income are primarily due to the foreign entity being taxed at a lower rate and certain nondeductible items, as follows.

F-13

| | 2005 | 2004 | 20 |
|--|------------|----------|-------|
| Income tax/(benefit) at federal statutory rate (34%) | \$ (2,536) | \$ 854 | \$ 1 |
| State tax | (194) | (162) | |
| Valuation allowance | 2,589 | 899 | |
| Foreign tax differential | (303) | (293) | |
| Other | 8 | 8 | |
| | ----- | ----- | ----- |
| Total | \$ (436) | \$ 1,306 | \$ 1 |
| | ===== | ===== | ===== |

The tax effect of the temporary differences that give rise to the Company's net deferred taxes as of September 30, 2005, and 2004 are as follows:

| | 2005 | 2004 |
|------------------------------|---------|---------|
| Assets | | |
| Deferred tax assets: | | |
| Current: | | |
| Other Liabilities | 70 | 70 |
| Management Fees | 402 | 231 |
| Bad debt reserve | \$ 44 | \$ 35 |
| Inventory reserve | 594 | 337 |
| Insurance reserve | 39 | - |
| | ----- | ----- |
| Subtotal | 1,149 | 673 |
| | ----- | ----- |
| Noncurrent: | | |
| Net operating loss & credits | 7,006 | 5,158 |
| Distribution Fees | 786 | 673 |
| Other Liabilities | 70 | 70 |
| | ----- | ----- |
| Deferred tax asset | 9,011 | 6,574 |
| | ----- | ----- |
| Liability | | |
| Deferred tax liability: | | |
| Noncurrent: | | |
| Fixed assets | (225) | (224) |
| Deferred revenue | (96) | (84) |
| | ----- | ----- |
| Subtotal | (321) | (308) |
| | ----- | ----- |
| Valuation allowance | (6,309) | (4,523) |
| | ----- | ----- |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

Net deferred tax asset \$ 2,381 \$ 1,743
===== =====

The Company has recorded a valuation allowance to reflect the estimated amount of deferred tax assets that may not be realized due to the expiration of net operating losses and tax credit carryovers. The net increase in the valuation allowance is comprised primarily of increases in federal and state net operating losses and credit carryovers, which may not be realized.

The Company has approximately \$14,900 of federal net operating loss carryforwards expiring beginning in 2008, a \$21 AMT credit carryforward, and a \$21 credit on research and development that will expire in 2013 if unused. The Company also has state net operating loss carryforwards of approximately \$14,400 that will begin to expire in 2006.

The Company has a corporate net operating loss carryforward for German income tax purposes of approximately \$3,677 (3,052 Euros), and a trade net operation loss carryforward for German income tax purposes of approximately \$1,241 (1,030 Euros), which can be carried forward indefinitely. The Company continually reviews the adequacy and necessity of the valuation allowance in accordance with the provisions of SFAS No. 109, ACCOUNTING FOR INCOME TAXES. As of September 30, 2005, the Company has recorded a valuation allowance on deferred tax assets related to its U.S. operations.

The Company has not recorded deferred income taxes on the undistributed earnings of its foreign subsidiaries because it is management's intent to indefinitely reinvest such earnings. Upon distribution of these earnings, the Company may be subject to U.S. income taxes and/or foreign withholding taxes.

F-14

11. EARNINGS PER SHARE

The following is a reconciliation of the numerators and denominators of the basic and diluted (loss) earnings per share computations for the years ended September 30, 2005, 2004 and 2003. The Company has excluded 419 shares of stock options for the diluted loss per share calculation for the year ended September 30, 2005 as such options are anti-dilutive to the calculation:

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNT DATA)

| | NET (LOSS) INCOME | SHARES | PER SHARE AMOUNT |
|-----------------------------|----------------------|------------|---------------------|
| 2005 | | | |
| Basic loss per share | \$ (7,017) | 15,919,286 | \$ (0.44) |
| Effect of dilutive secured: | | | |
| Stock options | - | - | - |
| | ----- | ----- | ----- |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | |
|-----------------------------|------------|------------|-----------|
| Diluted loss per share | \$ (7,017) | 15,919,286 | \$ (0.44) |
| | ===== | ===== | ===== |
| 2004 | | | |
| Basic earnings per share | \$ 1,133 | 15,734,470 | \$ 0.07 |
| Effect of dilutive secured: | | | |
| Stock options | - | 734,973 | - |
| | ----- | ----- | ----- |
| Diluted earnings per share | \$ 1,133 | 16,469,443 | \$ 0.07 |
| | ===== | ===== | ===== |
| 2003 | | | |
| Basic earnings per share | \$ 3,707 | 15,495,148 | \$ 0.24 |
| Effect of dilutive secured: | | | |
| Stock options | - | 600,300 | (0.01) |
| | ----- | ----- | ----- |
| Diluted earnings per share | \$ 3,707 | 16,095,448 | \$ 0.23 |
| | ===== | ===== | ===== |

12. COMMITMENTS AND CONTINGENCIES

The Company currently has operating leases for its corporate offices in the U.S. and Germany, as well as several leases related to office equipment and automobiles. Total rental expense was \$1,212, \$1,103 and \$759 for the years ended September 30, 2005, 2004 and 2003, respectively. Future minimum rental payments required under these leases that have initial or remaining noncancelable lease terms in excess of one year as of September 30, 2005 are as follows:

| | |
|------------|----------|
| 2006 | \$ 1,064 |
| 2007 | 787 |
| 2008 | 632 |
| 2009 | 557 |
| 2010 | 300 |
| Thereafter | - |
| | - |
| | ----- |
| | \$ 3,340 |
| | ===== |

F-15

The Company is party to various claims, legal actions, complaints and administrative proceedings arising in the ordinary course of business. In management's opinion, the ultimate disposition of these matters will not have a material adverse effect on its financial condition, cash flows or results of operations. In 2003, the Company received a proposed judgment in Germany as the result of a dispute between the Company and a former international distributor. The estimated settlement, including legal costs was accrued as a litigation contingency. In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

original proposed judgment received against the Company by \$406. At September 30, 2005 and 2004, the Company maintains an accrual of \$476 with respect to the remaining appeal and legal costs. Management believes that such accrual is sufficient and the final settlement will not have a material impact on its results of operations or financial position.

13. RELATED PARTY

The Company has an exclusive license and distribution agreement with Zimmer Spine, a wholly owned subsidiary of Zimmer Holdings, Inc., whereby Zimmer Spine has been granted the right to act as the Company's exclusive distributor of bone tissue for spinal applications in the United States. For the years ended September 30, 2005, 2004 and 2003 product sales to Zimmer spine totaled \$3,318, \$4,850 and \$4,999, respectively. Representing 10.4%, 16.5% and 16.5% respectively of our total revenues. Accounts receivable from Zimmer Spine were \$44 and \$723 at September 30, 2005 and 2004 respectively.

The Company has also engaged Zimmer Dental, a wholly owned subsidiary of Zimmer Holdings, Inc., to act as an exclusive distributor for the Company's bone tissue for dental applications in the United States and certain international markets. Under this distribution agreement, the Company sells directly to Zimmer Dental's customers. For the years ended September 30, 2005, 2004 and 2003, Zimmer Dental was paid commissions aggregating approximately \$6,055, \$3,213 and \$1,654, respectively. Accounts payable to Zimmer Dental total \$1,740 and \$1,456 at September 30, 2005 and 2004.

Zimmer CEP (formerly Centerpulse) USA Holding Co., a subsidiary of Zimmer Holdings, Inc., is a significant owner of the Company's outstanding shares of Common Stock.

14. SUBSEQUENT EVENT

On October 12, 2005, the Company issued a voluntary recall of all product units, which utilized donor tissue received from BioMedical Tissue Services/BioTissue Recovery Services ("BioMedical"). This action was taken because the Company was unable to satisfactorily confirm that BioMedical had properly obtained donor consent. The Company quarantined all BioMedical products in its inventory, having a value of \$1,046, and has notified all customers and distributors of record regarding this action. In connection with this recall, the Company wrote-off \$174 of inventory and accrued \$872 of inventory reserve and \$250 of other related costs at September 30, 2005.

15. SELECTED QUARTERLY FINANCIAL DATA (Unaudited)

The following is a summary of unaudited quarterly financial results for the year ended September 30, 2005:

| (in 000's, except per share data) | December 31, 2004 | | March 31, 2005 | | June 30, 2005 | |
|--------------------------------------|------------------------------|--------------------|------------------------------|--------------------|------------------------------|--------------------|
| | As Previously Reported | As Restated (a) | As Previously Reported | As Restated (a) | As Previously Reported | As Restated (a) |
| Revenues | \$ 7,073 | \$ 7,073 | \$ 7,554 | \$ 7,554 | \$ 9,281 | \$ 9,281 |
| Gross Profit | 3,313 | 2,781 | 2,753 | 2,863 | 3,025 | 3,025 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | | | | |
|--------------------|-----------|-----------|-----------|-----------|-----------|----|
| Operating expenses | 4,243 | 4,243 | 4,527 | 4,527 | 4,683 | |
| Operating loss | (930) | (1,462) | (1,774) | (1,664) | (1,658) | |
| Net loss | (1,382) | (1,914) | (1,239) | (1,129) | (1,432) | |
| Loss per share | | | | | | |
| Basic | \$ (0.09) | \$ (0.12) | \$ (0.08) | \$ (0.07) | \$ (0.09) | \$ |
| Diluted | \$ (0.09) | \$ (0.12) | \$ (0.08) | \$ (0.07) | \$ (0.09) | \$ |

(a) As restated, see Note 16.

F-16

The following is a summary of unaudited quarterly financial results for the year ended September 30, 2004:

| (in 000's, except per share data) | December 31, 2003 | | March 31, 2004 | | June 30, 2004 | |
|--------------------------------------|------------------------------|--------------------|------------------------------|--------------------|------------------------------|--------------------|
| | As Previously Reported | As Restated (a) | As Previously Reported | As Restated (a) | As Previously Reported | As Restated (a) |
| Revenues | \$ 7,485 | \$ 7,485 | \$ 7,089 | \$ 7,089 | \$ 6,823 | \$ 6,823 |
| Gross Profit | 4,496 | 4,485 | 5,091 | 4,522 | 4,536 | 4,536 |
| Operating expenses | 3,638 | 3,638 | 3,899 | 3,899 | 3,466 | 3,466 |
| Operating loss | 858 | 847 | 1,192 | 623 | 1,070 | 1,070 |
| Net income (loss) | 582 | 571 | 653 | 84 | 635 | 635 |
| Earnings (loss) per share | | | | | | |
| Basic | \$ 0.04 | \$ 0.04 | \$ 0.04 | \$ 0.01 | \$ 0.04 | \$ 0.04 |
| Diluted | \$ 0.04 | \$ 0.04 | \$ 0.03 | \$ 0.01 | \$ 0.04 | \$ 0.04 |

(a) As restated, see Note 16.

16. RESTATEMENT

As part of the financial review for the three and six months ended March 31, 2006, the Company became aware of misstatements in previously reported inventory and cost of revenue. The Company discovered that the misstatements were attributable to errors in the calculation of intercompany profit to be eliminated during the consolidation process for prior periods. While investigating in inventory errors, the Company also discovered other errors affecting the Company's deferred tax benefit, accrued expenses, general and administrative and distribution and marketing expenses for the fiscal year ended September 30, 2005. As a result, the Company has restated the accompanying consolidated financial statements for the years ended September 30, 2005, 2004, and 2003 to correct these errors.

The cumulative effect of these errors on accumulated deficit and total shareholders' equity as of the beginning of the year ended September 30, 2003 was an increase of \$1,885 and a reduction of \$1,885, respectively.

F-17

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

The impact of this restatement on the accompanying consolidated financial statements is summarized below:

| FOR THE YEAR ENDED SEPTEMBER 30, 2005 | As Previously Reported | Adjustments |
|--|------------------------------|-------------|
| Cost of revenues | \$ 20,295 | \$ 215 |
| Gross profit | 11,565 | (215) |
| General and administrative expenses | 5,371 | 38 |
| Distribution and marketing expenses | 11,501 | 8 |
| Operating loss | (6,966) | (261) |
| Income tax benefit | (571) | 135 |
| Net loss | (6,621) | (396) |
| Foreign currency translation (loss) | (770) | 200 |
| Comprehensive loss | (7,391) | (196) |
| Basic loss per share | (0.42) | (0.02) |
| Diluted loss per share | (0.42) | (0.02) |
| Cash flows from operating activities: | | |
| Net loss | (6,621) | (396) |
| Deferred income taxes | (571) | 66 |
| Changes in inventories | 3,508 | 263 |
| Changes in accounts payable and other accrued expenses | (566) | 69 |
| AS OF SEPTEMBER 30, 2005: | | |
| Inventories, net | 10,558 | (1,004) |
| Deferred tax asset | 2,314 | 67 |
| Accounts payable and other accrued expenses | 6,273 | 69 |
| Accumulated other comprehensive income | 1,478 | 200 |
| Acculated deficit | (23,290) | (1,206) |
| Shareholders' equity | 14,728 | (1,006) |
| | | |
| FOR THE YEAR ENDED SEPTEMBER 30, 2004 | As Previously Reported | Adjustments |
| Cost of revenue | \$ 11,836 | \$ 370 |
| Gross profit | 17,494 | (370) |
| Net income | 1,503 | (370) |
| Basic loss per share | 0.10 | (0.03) |
| Diluted loss per share | 0.09 | (0.02) |
| Cash flows from operating activities: | | |
| Net loss | 1,503 | (370) |
| Changes in inventories | (1,824) | 370 |
| AS OF SEPTEMBER 30, 2004: | | |
| Inventories, net | 15,072 | (811) |
| Accumulated deficit | (16,669) | (810) |
| Shareholders' equity | 22,083 | (811) |
| | | |
| FOR THE YEAR ENDED SEPTEMBER 30, 2003 | As Previously Reported | Adjustments |
| Cost of revenue | \$ 11,640 | \$ (1,445) |
| Gross profit | 18,620 | 1,445 |
| Net income | 2,262 | 1,445 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | |
|---------------------------------------|---------|---------|
| Basic loss per share | 0.15 | 0.09 |
| Diluted loss per share | 0.14 | 0.09 |
| Cash flows from operating activities: | | |
| Net loss | 2,262 | 1,445 |
| Changes in inventories | (2,545) | (1,445) |

F-18

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of
Tutogen Medical, Inc. and Subsidiaries
West Paterson, New Jersey

We have audited the consolidated financial statements of Tutogen Medical, Inc. and subsidiaries (the "Company") as of September 30, 2005 and 2004, and for each of the three years in the period ended September 30, 2005, and have issued our report thereon dated December 8, 2005 (July 5, 2006 as to the effects of the restatement discussed in Note 16) (which report expresses an unqualified opinion and includes an explanatory paragraph concerning the restatement as discussed in Note 16); such financial statements and report are included elsewhere herein. Our audits also included the financial statement schedule of the Company listed in the accompanying Index at Item 15B. This financial statement schedule is the responsibility of the Company's management. Our responsibility is to express an opinion based on our audits. In our opinion, such financial statement schedule, when considered in relation to the basic financial statements taken as a whole, present fairly in all material respects the information set forth therein.

/s/ Deloitte & Touche LLP
Certified Public Accountants
Orlando, Florida
December 8, 2005

TUTOGEN MEDICAL, INC.
SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS
YEARS ENDED SEPTEMBER 30, 2005, 2004 AND 2003

| | Balance at Beginning of Period | Additions (Reversals) Charged to (Credited) to Costs and Expenses | Deduc |
|----------------------------------|--------------------------------------|--|-------|
| Allowance for doubtful accounts: | | | |
| YEAR ENDED SEPTEMBER 30, 2005 | \$ 192 | \$ 308 | \$ |
| Year ended September 30, 2004 | 429 | (83) | |
| Year ended September 30, 2003 | 193 | 264 | |
| Allowance for product returns | | | |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-K/A

| | | | | | |
|-------------------------------|----|-----|----|-----|----|
| YEAR ENDED SEPTEMBER 30, 2005 | \$ | 241 | \$ | 183 | \$ |
| Year ended September 30, 2004 | | 117 | | 124 | |
| Year ended September 30, 2003 | | 0 | | 117 | |

Allowance for obsolescence

| | | | | | |
|-------------------------------|----|-------|----|-------|----|
| YEAR ENDED SEPTEMBER 30, 2005 | \$ | 2,210 | \$ | 1,460 | \$ |
| Year ended September 30, 2004 | | 2,981 | | (597) | |
| Year ended September 30, 2003 | | 1,757 | | 1,434 | |

Valuation allowance for net deferred tax assets:

| | | | | | |
|-------------------------------|----|-------|----|-------|----|
| YEAR ENDED SEPTEMBER 30, 2005 | \$ | 4,523 | \$ | 1,786 | \$ |
| Year ended September 30, 2004 | | 3,496 | | 1,027 | |
| Year ended September 30, 2003 | | 3,906 | | 0 | |

(1) Net write-offs and recoveries.